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1 ABSTRACT
Various reasons, such as ethical issues in maintaining blood resources, growing 
costs, and strict requirements for safe blood, have increased the pressure for efficient 
use of resources in blood banking. The competence of blood establishments can be 
characterized by their ability to predict the volume of blood collection to be able 
to provide cellular blood components in a timely manner as dictated by hospital 
demand. The stochastically varying clinical need for platelets (PLTs) sets a specific 
challenge for balancing supply with requests. Labour has been proven a primary 
cost-driver and should be managed efficiently. International comparisons of blood 
banking could recognize inefficiencies and allow reallocation of resources.
Seventeen blood centres from 10 countries in continental Europe, Great Britain, 
and Scandinavia participated in this study. The centres were national institutes (5), 
parts of the local Red Cross organisation (5), or integrated into university hospitals 
(7). This study focused on the departments of blood component preparation of the 
centres. The data were obtained retrospectively by computerized questionnaires 
completed via Internet for the years 2000-2002. The data were used in four original 
articles (numbered I through IV) that form the basis of this thesis. Non-parametric 
data envelopment analysis (DEA, II-IV) was applied to evaluate and compare the 
relative efficiency of blood component preparation. Several models were created 
using different input and output combinations. The focus of comparisons was on the 
technical efficiency (II-III) and the labour efficiency (I, IV). An empirical cost model 
was tested to evaluate the cost efficiency (IV). Purchasing power parities (PPP, IV) 
were used to adjust the costs of the working hours and to make the costs comparable 
among countries. 
The total annual number of whole blood (WB) collections varied from 8,880 to 
290,352 in the centres (I). Significant variation was also observed in the annual 
volume of produced red blood cells (RBCs) and PLTs. The annual number of PLTs 
produced by any method varied from 2,788 to 104,622 units. In 2002, 73% of all PLTs 
were produced by the buffy coat (BC) method, 23% by aphaeresis, and 4% by the 
platelet-rich plasma (PRP) method. The annual discard rate of PLTs varied from 3.9% 
to 31%. The mean discard rate (13%) remained in the same range throughout the 
study period and demonstrated similar levels and variation in 2003-2004 according 
to a specific follow-up question (14%, range 3.8%-24%). The annual PLT discard 
rates were, to some extent, associated with production volumes. The mean RBC 
discard rate was 4.5% (range 0.2%-7.7%). 
Technical efficiency showed marked variation (median 60%, range 41%-100%) 
among the centres (II). Compared to the efficient departments, the inefficient 
departments used excess labour resources (and probably) production equipment to 
produce RBCs and PLTs. Technical efficiency tended to be higher when the (theoretical) 
proportion of lost WB collections (total RBC+PLT loss) from all collections was low 
(III). The labour efficiency varied remarkably, from 25% to 100% (median 47%) 
when working hours were the only input (IV). Using the estimated total costs as 
the input (cost efficiency) revealed an even greater variation (13%-100%) and 
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overall lower efficiency level compared to labour only as the input. In cost efficiency 
only, the savings potential (observed inefficiency) was more than 50% in 10 
departments, whereas labour and cost savings potentials were both more than 50% 
in six departments. The association between department size and efficiency (scale 
efficiency) could not be verified statistically in the small sample. 
In conclusion, international evaluation of the technical efficiency in component 
preparation departments revealed remarkable variation. A suboptimal combination 
of manpower and production output levels was the major cause of inefficiency, and 
the efficiency did not directly relate to production volume. Evaluation of the reasons 
for discarding components may offer a novel approach to study efficiency. DEA 
was proven applicable in analyses including various factors as inputs and outputs. 
This study suggests that analytical models can be developed to serve as indicators 
of technical efficiency and promote improvements in the management of limited 
resources. The work also demonstrates the importance of integrating efficiency 
analysis into international comparisons of blood banking.  
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2 LIST OF ORIGINAL ARTICLES 
This thesis is based on the following original articles, which are referred to in the 
text by their Roman numerals (I-IV).
I Veihola M, Aroviita P, Linna M, Sintonen H, Kekomäki R. Variation of platelet 
production and discard rates in 17 blood centres representing 10 European countries 
from 2000 to 2002. Transfusion 2006; 46 (6): 991-5.
II  Veihola M, Aroviita P, Linna M, Sintonen H, Kekomäki R. International comparison 
of the technical efficiency of component preparation. Transfusion 2006; 46 (12): 
2109-14.
III Veihola M, Aroviita P, Kekomäki R, Linna M, Sintonen H. Discarded cellular 
components and the technical efficiency of component preparation. The European 
Journal of Health Economics 2007 Oct 26 (Epub ahead of print). 
IV Veihola M, Kekomäki R, Linna M, Sintonen H, Aroviita P. Working hours and 
produced cellular components as variables to evaluate blood bank efficiency. 
Transfusion Medicine, 2008, 18, 241-249.
The original articles are reprinted with permission from the copyright holders.
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3 ABBREVIATIONS
BC buffy coat 
CRS constant returns to scale
D blood component preparation department
DEA data envelopment analysis
DRS decreasing returns to scale
FFP fresh-frozen plasma
IRS increasing returns to scale
OECD Organisation of Economic Co-operation and Development
p probability value
PAS platelet additive solution
PLT platelet
PPP purchasing power parity
PRP platelet-rich plasma
r correlation coefficient
RBC red blood cell
SD standard deviation
VRS variable returns to scale
WB whole blood
WBC white blood cell, leukocyte
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4 INTRODUCTION
In modern transfusion therapy, donated blood is not transfused to the patient as-is but 
is instead reduced to blood products, which was made possible by the development 
of plastic bags (Walter C and Murphy W, 1952). After this invention, associated 
preparation methods were developed (Slichter SJ and Harker LA, 1976), and cellular 
blood products, RBCs and PLTs are derived by various techniques; for example, RBCs 
can be produced by preparative centrifugation and PLTs by alternative methods.  
In Europe, WB-derived or BC-derived PLT production has been adopted by several 
countries (Murphy S, 2005; Murphy S et al., 1996). In the BC method, RBCs and PLTs are 
prepared by centrifugation of a WB unit obtained from a donor. A PRP method, commonly 
used earlier in the European blood community, has been almost totally replaced by the 
BC method. In the U.S., PLTs are often derived from a donor by using an automated cell 
separator (a method of aphaeresis) (Devine P et al., 1996). Theoretically, if 100% of PLTs 
were collected by aphaeresis, all PLTs from WB donations would be discarded. In the BC, 
PRP, and aphaeresis methods, blood plasma can be collected to be used either freshly 
frozen (fresh-frozen plasma, FFP), or fractionated further to medicinal products.
Blood collection and processing are carried out by authorized blood service 
organization(s) according to the respective national health policy of each country. 
Where not organized by government, blood service operations can be delegated to 
other institutes, the local Red Cross, communes, or hospitals. In Europe, the blood 
establishments and blood banks are governed by the blood directive (European 
Commission, 2004) and the recommendations in the “Guide to the preparation, use 
and quality assurance of blood components” by the Council of Europe (Guide, 2007). 
Therefore, the blood components in the EU may be considered similar.
Blood and blood components are subject to regular measures of ensuring their 
safety, efficacy, and quality. Special emphasis is put on selecting healthy donors and 
screening donors for infectious markers of blood-transmittable microbes. New tests 
and safety measures have increased expenditure at blood establishments. 
Blood components are inadvertently wasted throughout the supply chain. Most of 
the losses, however, are due to the expiration of the products. A short shelf life and 
unexpected variation in the demand of PLTs emphasize the importance of managing 
economic and human resources at blood establishments. 
Blood establishments devote considerable resources to the production of blood 
components, considered a core process of blood banking, and a significant part of blood 
processing costs are attributed to labour costs (Amin M et al., 2004). The efficiency of 
component preparation, however, has been rarely studied (Butch SH, 1998; Pitocco C 
and Sexton TR, 2005; Pereira A, 2006). Benchmarking may help blood establishments 
identify ways to meet the demand, especially in a situation of a narrowing margin 
between blood donation and transfusion, as well as under economic constraints.
The present study was ethically justified, as the blood establishments are 
reimbursed by hospitals for the blood products and are responsible to the blood 
donors for optimal use of their gift.
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5 REVIEW OF THE LITERATURE
5.1 managemenT of blood Transfusions
As a special characteristic, blood establishments cannot predict production according 
to availability of blood only; they also need to respond to varying demand from 
hospitals. Close collaboration between suppliers (blood establishments and blood 
banks) and users (hospitals) is of utmost importance in the efficient management of 
blood resources. The present study does not include the stages of management from 
the delivery of blood products to the hospital or from the hospital blood bank to the 
patient for transfusion.
5.1.1 blood supply and demand
Donor recruitment, donor screening, and blood collection are inherent activities in 
maintaining a sufficient blood supply. Donor recruitment has become a delicate issue 
as donors become less available because of socio-demographic changes in population 
and because screening requirements are increasingly strict (Brittenham GM et al., 
2001; Reynolds E et al., 2001). 
There is a clear downward trend in RBC demand and utilization in Europe, as 
reported by the EBA (European Blood Alliance) benchmarking project from 11 
countries (Gorham M, 2007). On  the other hand, the number of transfusions has 
been reported to increase, contributing to an even chronic shortage of RBCs in the 
U.S. (Pitocco C and Sexton TR, 2005; Sullivan MT et al., 2007). Blood is a perishable 
resource, and contributing to its further replenishing through regular, voluntary, 
and non-remunerated donations has raised questions, for example, about changing 
the age criteria of donors or using automated technology by collecting two RBC 
units from a single donor (Gilcher RO, 2003; Goldman M et al., 2007). 
The number of WB collections is predicted by hospital demand for RBCs. Accordingly, 
blood establishments aim to plan for WB collections to correspond to the basic clinical 
need and to balance them with the blood group distribution in the population. To satisfy 
the often stochastic demand for PLTs, blood establishments may use supplementary 
methods, such as aphaeresis, to derive more units of PLTs at a time (Snyder EL et 
al., 2003; Vassallo RR, Jr. et al., 2004). Efficient management over the whole supply 
chain with special attention to the inventory would assure an optimal supply of RBCs 
and PLTs and decrease the expiration of the components.
5.1.2 rbc transfusions 
The main purpose of RBC transfusion is to improve the delivery of oxygen to 
the tissues. The physiology of oxygen delivery has been described, whereas the 
appropriate universal trigger for transfusion, such as haemoglobin concentration 
(Weiskopf RB et al., 1998; Lieberman JA et al., 2000) or haematocrit value 
(Crowell JW and Smith EE, 1967) remains controversial. Thus, clinical practices 
in the use of RBCs vary widely. The Safe and Good Use of Blood in Surgery study 
compared the usage of blood components in elective surgical procedures among 
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43 European teaching hospitals and detected a variation in the risk of receiving 
transfusions for equivalent procedures from 0% to 100% among the hospitals 
(SANGUIS, 1994). Another study revealed a six-fold variation in the mean number 
of blood components transfused per patient in coronary artery bypass grafting 
(CABG) operations in nine Finnish hospitals (Kytola L et al., 1998).
Most RBC transfusions are administered to surgical and intensive care patients 
(Vincent JL et al., 2002; Rao MP et al., 2002). According to a Finnish study, more 
than half of 59,535 transfusions were conducted during surgical operations (Palo R 
et al., 2005). The majority of RBCs were transfused to surgical patients undergoing 
either cardiac or orthopaedic surgery (Capraro L and Syrjala M, 2001). Chronic 
or congenital anaemia may also indicate RBC transfusion. A recent study reports 
a wide variation in the incidence rate of RBC transfusions in the U.S., Australia, 
England, and Denmark, from 44.7 to 54.1 units per 1,000 population (Cobain TJ et 
al., 2007). In Europe, the incidence rate was highest in Denmark, Greece, Austria, 
and Finland, where more than 52 RBC products per 1,000 population were used, 
whereas in several other countries, the rate varied from 30 to 40 units (European 
Health Committee (CDSP), http://www.coe.int/t/dg3/health/CDSP_en.asp). According 
to U.S. data from 1989-1992, more than 53% of all RBC components were transfused 
into patients over 65 years of age (Vamvakas EC and Taswell HF, 1994). The trend 
is similar in Europe (Wells AW et al., 2002); thus, elderly patients may be an 
expanding group of transfusion recipients.
In the U.S., according to a large survey covering 2,247 blood centres and banks, 
transfusions of WB and RBCs increased by 12.2% from 1999 to 2001 (Sullivan MT 
and Wallace EL, 2005).  
Based on current usage, the demand for blood products is expected to exceed 
the supply within 20 years (Currie CJ et al., 2004). European studies have reported 
a decrease during recent years in the use of RBCs in elective surgeries. RBC 
transfusions decreased in CABG surgeries from 47% in 1997/1998 to 31.6% in 
2001/2002 in British hospitals (Cobain TJ, 2004). The number of donor exposures, 
including the CABG patients, decreased from 76% in 1998 to 48% in 1999 in a 
Finnish study (Capraro L and Syrjala M, 2001). A wide variation in the incidence 
rate of RBC transfusions internationally, even in Europe, may require varying the 
relative amount of resources used by blood establishments to respond to the 
demand for RBCs. 
5.1.3 plT transfusions
PLTs may be transfused when a low PLT count (thrombocytopenia) is observed in 
diseases that affect their production or function, such as leukaemia, aplastic anaemia, 
cancer, congenital defects, trauma, and viral infections. Most PLT transfusions are 
prophylactic to prevent bleeding in thrombocytopenic haematological patients or 
are given therapeutically to stop haemorrhage, whereas only 15% are transfused 
in surgical procedures (Simon TL, 1991). Triggers for prophylactic PLT transfusions 
have been discussed in many studies, but a single PLT threshold value does not 
apply to different situations.
Among the U.S., Australia, England, and Denmark, a major variation was recently 
reported in the incidence rate for PLT transfusions, from 2 to 6 units per 1,000 
inhabitants per year (Cobain TJ et al., 2007).
| 12 |
According to multiple reports, the demand for PLTs has shown a tendency to increase 
(Critchfield GC et al., 1985; Sullivan MT and Wallace EL, 2005). Nearly 10.2 million 
units of PLTs were transfused in the U.S. in 2001, an increase of 12.6% over the 
number of units transfused in 1999. The trend is similar in Europe. Demand for PLTs 
rose by 450% in Wales U.K. from 1980-1992 (Booth T et al., 1992) and doubled in 
Switzerland from 1991-1995 (Nydegger UE and Schneider P, 1997). Also in Finland, 
the clinical use of PLTs has been increasing (Finnish Red Cross Blood Service, 2006). 
It seems obvious that the use of PLTs will continue to grow for various indications.     
A short shelf life (5-7 days) of PLTs is a critical factor that sets up a challenge for 
the blood centre and the hospital. Again, varying the amount of resources may be 
needed locally to satisfy the demand for PLTs in a timely way.
           .
5.2 from blood To blood producT
The path from blood to blood products is a demanding technological process that 
starts with collection of WB and ends with RBC and PLT products (Figure 1). Discarded 
products comprise those wasted in production and those that are outdated. Collection 
of PLTs by aphaeresis can be used to supplement PLT production, and sophisticated 
production materials and equipment have been developed for this purpose. For 
issuing blood products to hospitals, blood establishments may be reimbursed at a 
price estimated to equal the production cost of the manufacturing processes. 
figure 1 The operations of a blood establishment
5.2.1 blood service systems 
The organisation of blood transfusion services has been an issue of national policy. 
Where government has not undertaken this task, blood service operations have 
been delegated to the local Red Cross, hospital blood banks, not-for-profit institutes, 
or commercial organisations. Plasma fractionation is concentrated on commercial 
plasma fractionation companies or larger scale pharmaceutical enterprises. 
In all of the Nordic countries with the exception of Finland, hospitals or communes 
are responsible for blood banking. A centralized system for blood collection, 
produced rbcs
discarded rbcs/plTs
paTienT 
aT hospiTal
Wb 
collections
aphaeresis- 
plTs
Production
produced plTs
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processing, and distribution has been entrusted to the Red Cross in countries such 
as Australia, Canada, the U.S., Switzerland, Belgium, Austria, Germany, Greece, 
Spain, and Finland, although other involved institutes may coexist (Leikola J, 
2004; Tretiak R et al., 1996; Tretiak R et al., 1996). 
A national, centralized blood service system has been adopted by France and the 
U.K., organized by the government nationwide. In the U.K., one national blood service 
(NBSNHS) governed by the National Health Service (NHS) authority has been formed 
from the 14 (until 1993) previously independent blood services. There is a similar 
trend towards centralization in countries with large networks of hospital blood banks, 
particularly in Sweden and Norway. 
5.2.2 blood collection
More than 75 million units of blood are collected annually worldwide (Red Cross 
Red Crescent – Blood Services). Of these, voluntary unpaid donations cover 92% 
in developed countries and 67% in developing countries (Blood transfusion, http://
www.who.int/topics/blood_transfusion/en). In the U.S., 15.3 million WB units were 
collected in 2001 (Sullivan MT et al., 2007).
Donor recruitment and blood collection are likely the most critical parts of blood 
establishments. Blood donors have become less available compared to the growing 
demand for blood products. New recruitment techniques have been adapted to 
induce new donors, and donation criteria may have been mitigated, for example, 
by extending the age limits, to retain regular donors (van der Pol MM and Cairns JA, 
1998; Smith JW et al., 2002; Smith JW et al., 2002). Multicomponent aphaeresis 
for deriving combinations of RBC, PLT, and plasma units (Waxman DA, 2002) and 
collection of double RBC units are increasingly used to alleviate blood shortages, 
especially in the U.S. (AuBuchon JP et al., 2007). 
Because blood collections are driven by the demand for the RBCs, blood banks tend 
to pre-estimate the mere clinical use of blood products in hospitals to balance the 
collections accordingly. The choice of collection bag has been determined by the aims of 
production; that is, optimising BC separation, maximising RBC recovery, or maximising 
plasma harvest (van Rhenen DJ et al., 1998). Recruiting donors and maintaining the 
donor base will challenge blood establishments because these activities will become 
more costly and require greater effort in the future. Blood establishments need to 
explore strategies that allow the collections to be performed at a lower cost and, at the 
same time, assure a sufficient supply of blood (van der Pol M et al., 2000). 
5.2.3 component preparation
A common goal of component preparation methods is to produce RBCs, PLTs, and 
FFP that contain maximum amounts of therapeutic blood elements and minimum 
amounts of unnecessary residual cells. The separation of blood into its components 
can be accelerated by centrifugation, which is based on different physicochemical 
properties, such as density of blood cells. Changing centrifugation parameters, such 
as time, temperature, and rotation speed can affect the composition of separated 
fractions. With the development of the processing technique, blood component 
preparation has become a routine procedure worldwide (van Delden CJ et al., 1998; 
Heaton WA et al., 1997).
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Removal of white blood cells (WBCs) from blood components (leukocyte reduction) 
has been established to obtain less-contaminated blood concentrates to prevent febrile 
reactions following blood transfusions and to reduce alloimmunization (Uhlmann EJ 
et al., 2001; Pruss A et al., 2004; Capraro L et al., 2007). RBCs and PLTs can be 
filtered after the separation to obtain leukocyte-reduced components. RBCs can also 
be derived from WB that has been filtered to remove leukocytes (Riggert J et al., 
1997). In this procedure, even PLTs are lost.     
The production methods of PLTs (PRP and BC methods) vary in different areas 
of the world. About 75% of the PLTs (therapeutic doses) transfused in the U.S. are 
obtained by aphaeresis (single-donor PLTs) and 25% are prepared from WB using 
the PRP method. The number of single-donor PLTs transfused increased by 26% from 
1999 to 2001, whereas the use of WB-derived PLTs declined by 13.9% (Sullivan MT et 
al., 2007). In Europe, 14 countries reported that about 44% of transfused PLTs were 
derived from BC, 49% from aphaeresis, and only 7% from PRP (Murphy S, 2005). 
In studies of the clinical advantages, e.g., the therapeutic efficacy, both WB-derived 
PLTs and aphaeresis-PLTs are comparable in their ability to prevent and stop bleeding 
(Sloand EM et al., 1996). 
Figure 2 shows the processes of PLT production methods. BC and PRP methods 
are based on separation of blood components, RBCs, PLTs and plasma, from WB 
collection. In the BC method, 4-6 BCs are pooled to give one PLT concentrate. In the 
PRP method, the single-unit PLTs have been separated from PLT-rich plasma. The 
aphaeresis device allows both collection of the PLTs and preparation of the final PLT 
concentrate during collection.
Figure 2 The processes of the PLT production methods  
      Open arrows denote a centrifugation phase
PLt  
concentratePooling of 4-6 single-unit PLts
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PLt-rich plasma
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Buffy coat (BC) method   
Concern about the contamination of RBCs, the quality of PLTs, and the need for 
plasma derivatives contributed to the switch from the PRP method to the BC method 
in Europe (Prins HK et al., 1980; Murphy S, 2005). Technology for the removal of BC 
from a WB unit by manual techniques was initiated by the Finnish Red Cross Blood 
Service to use leukocytes in human interferon production. Therefore, the majority 
of leukocytes (approximately 90%) have been removed from all RBCs in Finland 
since 1979 (Oksanen K, 1994). The BC layer (PLT + WBC) was later launched as a 
source for PLT component preparation (Pietersz RN et al., 1987), first from single-
donor PLT units and later from BC pools. Pooling of PLTs was applied to increase the 
usability of PLTs and to save plasma while using the PLT additive solution (Eriksson 
L and Hogman CF, 1990). 
In the BC method, intense primary centrifugation of the WB unit allows separation 
of RBCs, the BC layer, and plasma. Further centrifugation of BC in PLT additive solution 
or plasma makes it possible to separate PLTs from WBCs and residual RBCs. If the 
aim is to prioritize obtaining pooled BCs, WB can be collected in a bag suitable for this 
purpose. Although PLTs can be obtained in sufficient amounts with current preparation 
methods, the short survival of PLTs is a challenge to their timely availability.
Today, processing of BCs to clinical PLT products is performed by semi-automated, 
closed, and sterile systems accompanied by several technological improvements, 
such as sterile connecting devices, the bottom-and-top bag system, separation 
devices, and new synthetic storage media (Hogman CF et al., 1988; Gulliksson H 
et al., 2002; Larsson S et al., 2005). Each prepared adult PLT concentrate should 
contain PLTs equivalent to the amount obtained from 4-6 WB collections (> 240 x 
109) (Guide, 2007).
Platelet-rich plasma (PRP) method
The PRP method has been a standard separation procedure since the introduction of 
plastic bags in the 1960s (Vassallo RR and Murphy S, 2006). The PRP continues to be 
commonly used in the U.S., but it has disappeared in Europe except in some southern 
areas (Murphy S, 2005). 
Aphaeresis method
The aphaeresis method allows deriving of four- to twelve-fold yield of PLTs in one donor 
session. Because of the smaller number of donor contacts for a patient, aphaeresis 
is also less prone to resulting in transmission of infections (Slichter SJ, 2007). 
Aphaeresis is costly, however, because the cell separation automation equipment, 
whether rented or purchased, is expensive, as are the disposable materials. Under 
certain conditions, however, aphaeresis is preferable. 
5.2.4 cellular components and fresh-frozen plasma
The bone marrow continuously produces new blood cells into the blood, where RBCs 
circulate with an average lifespan of 120 days, and PLTs, 7-10 days. Blood cells can 
be separated by centrifugation into at least three layers: RBC, BC, and plasma. The 
separation is improved after a so-called resting time of WB. Commonly used resting 
times vary from 2-8 hours to 16-24 hours (Oksanen K, 1994).
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RBCs  
One RBC unit is produced from one WB unit. The collection bag must contain the 
appropriate anticoagulant solution. Depending on the indication for use, RBCs are 
modified to be suitable for clinical use by BC removal, leukocyte reduction, washing, 
irradiation, or all of these procedures. A standard adult RBC unit should contain Hb 
at minimum 43 g/unit (Guide, 2007). Double (2) units of RBCs can be collected 
and processed at a time, which allows transfusion using units of higher Hb content 
(Snyder EL et al., 2003; Arslan O et al., 2004). RBCs can be stored before transfusion 
for 35 – 42 days at 2oC-8oC depending on the storage solution. The ABO and RhD 
compatibility of the donor and recipient must be ensured before transfusion.   
PLTs 
PLTs are prepared from units of WB collected from random donors into blood collection 
bags or alternatively, using a blood cell processor (aphaeresis) to collect one (to 
three) adult dose(s) of PLTs from a single donor. WB can be processed further for 
clinical use by centrifugation and separation procedures (the PRP or BC method) 
(Murphy S et al., 1996). The amount of PLTs in an adult standard dose is equivalent 
to the amount obtained from a pool of 4 to 6 units of WB. A BC-prepared PLT unit 
counts as more than 60 × 109 PLTs per single unit equivalent. The viability of PLTs is 
preserved from 5-7 days at 20oC to 24oC depending on storage conditions. Plasma or 
another solution is used as the storage liquid for PLTs (Guide, 2007).
FFP 
FFP is obtained either by separation of plasma from WB during preparation of RBCs 
and PLTs, or by plasmaphaeresis during PLT collection directly from a donor; thus, it 
can be considered a by-product of these processes. In either case, plasma is frozen 
no later than 8 hours after collection. FFP is used for clinical purposes or as source 
plasma for fractionation.  
5.2.5 discarded components
Blood components may be inadvertently wasted at any stage of the preparation 
(Cobain TJ, 2004). Hospitals across Canada were reported to waste on average 2% of 
RBC units per year, with the cost of wastage at less than a dollar per unit in a survey 
of eight hospitals (Amin M et al., 2004). In another Canadian study, the mean wastage 
rate in hospitals was 5% for RBCs (mean cost 5 USD/unit) (Tretiak R et al., 1996). 
The quality systems, however, assure that less wastage occurs during the production 
process by decreasing the deviations that lead to discards (Guide, 2007). Monitoring of 
the wastage and its causes has become a routine quality-assurance procedure in blood 
establishments (Clark JA and Ayoub MM, 1989; Novis DA et al., 2002). 
Because blood is perishable, the outdating of labile blood components, such as 
PLTs, has been considered the main reason for discards. A three-year statistical 
data analysis by the AABB from blood centres and blood banks showed a significant 
upward trend over time in the outdating or wastage of RBCs and PLTs (Devine P et 
al., 1996). Another large study reported a mean PLT discard rate of 18% in American 
blood banks in 1999 (Sullivan MT and Wallace EL, 2005). Because resources used 
to produce the discards are a lost production input and the discards represent lost 
revenue, discarded components should be subject to economic analysis in blood 
establishments.   
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Outdating of RBCs
Because the shelf life of RBCs is 35-42 days in blood service conditions, they are 
not as perishable as PLTs. Factors that affected enhanced expiration rates of RBCs 
in Australian public hospitals included, for example, the absence of a hospital 
transfusion committee, a high ratio of average stock levels, and premature cross-
matching of RBCs. Providing each of the hospital blood banks with individual 
improvement recommendations resulted in a significant reduction in the overall 
outdating rate from 5% to 1% (Pink J et al., 1994).  In the U.S., 6.3% of all collected 
RBC units were outdated in 2001 (Sullivan MT et al., 2007). At the same time, the 
unmet demand for the RBCs was estimated at 7.3%. Decreasing the outdating of 
RBCs, however, has not been the focus of studies seeking solutions for the chronic 
shortages of RBCs in the U.S. (Wallace EL, 2003; Gilcher RO, 2003). 
Outdating of PLTs
Additional expenditure by blood establishments has occurred because of the loss of 
PLTs because of their short shelf life (5-7 days) and the greatly varying demand for 
them. After a PLT unit has been released from all infection marker testing to delivery 
stock, the remaining shelf life may be only two days. Depending on the dose size of 
a PLT concentrate (e.g., four PLT units/adult dose), several units may be outdated 
at a time. As much as a fifth of produced PLT concentrates has been reported to 
become outdated (Sullivan MT and Wallace EL, 2005), and the expiration rate was 
more than 25% for random donor PLTs and more than 10% for aphaeresis-PLTs in 
every tenth blood bank of 1639 U.S. hospitals studied (Novis DA et al., 2002).
Methods allowing prolonged PLT survival, such as bacterial screening (Brecher 
ME and Hay SN, 2004; Blajchman MA et al., 2004), new preservation solutions, 
and cold storage (Hoffmeister KM et al., 2003) are highly desirable. High outdate 
rates may not be a necessary evil if the supply and production could be scaled 
to balance the stochastic need for PLTs, for example, by production planning and 
improving inventory management (Critchfield GC et al., 1985; Pink J et al., 1994). 
Independent of the basic production method, a flexible PLT production system 
would enhance responsiveness to meet demand peaks. 
5.2.6 inventory management
RBCs are obtained by every WB collection, whereas PLTs are derived from WB 
according to estimated transfusions for PLTs. Blood supply has been traditionally 
determined by the ability of the RBC supplies to meet transfusion demand. RBCs may 
not be sufficiently available, for example, because of sporadic shortages of donors, 
increased use, disruptions in production, or product recalls (Goodnough LT et al., 
2003; Sullivan MT et al., 2007). Planning and maintaining an adequate RBC inventory 
with ABO/Rh-typed units is based on better predictability of their need, such as for 
elective surgeries, and their longer shelf life. 
Supplies of PLTs have proven more complex to predict owing to their stochastic 
demand and short shelf life. While aiming at minimizing the outdating of blood 
components is an important economic issue, the primary task of inventory 
management is to assure the timely provision of blood products for transfusion.
Several techniques have been employed to monitor the stock levels, particularly 
of PLTs, to match supply to demand. Ledman and Groh established a committee 
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responsible for planning the PLT production based on everyday evaluations of 
PLT need in 60 hospitals (1984). The PLT outdate rate fell from 20% to 3%, and 
the need was satisfied over a 6-month period. Katz et al. developed a computer 
simulation model of PLT production and distribution (1983). Based on two years 
of PLT orders, the model generated daily orders and calculated mean demand and 
standard deviation of demand. The number of PLT concentrates to be produced 
each day was calculated with this information. The model was found to be 
applicable with a 5-day storage life for PLTs, regardless of the varying logistics 
of PLT production and distribution in the centres. The potential of time series 
models was investigated in the prediction of next-day PLT utilization (Critchfield 
GC et al., 1985). Simple mathematical models were found superior to one- or 
two-day moving averages, but they did not predict the day-of-the-week variation 
(seasonality) of PLT need more accurately than an experienced coordinator. 
Application of the time series model decreased the number of PLT outdates and 
resulted in significant savings in labour cost for the PLT inventory. 
Sirelson and Brodheim presented a computer model for PLT inventory management 
(1991). The model was based on the estimates of the mean values of PLT demand. 
Changes in the mean values predicted the shortage and outdate rate of PLTs in the 
inventory. A Finnish project for improving the supply chain involved, for example, 
tracking inventory levels at all stages of the chain with computer systems that were 
compatible between supplier and hospitals (Rautonen J, 2007). The other goal was 
to create a joint management system over hospital inventories, which would promote 
achieving deliveries that match with clinical need. Hospitals supported the idea of a 
collaborative approach. 
A decline of nearly 40% was marked in the margin between RBC supply and 
RBC transfusion demand from 1989 to 2001 in the U.S. (Sullivan MT et al., 2007). 
Nightingale et al. developed a system designed to detect the threat of shortages 
in real time. The system was based on daily reporting of transfusion service 
activities in a sample of large urban hospitals (2003). In the U.S., however, more 
than 90% of all WB units are collected by blood centres, which maintain buffering 
stocks for hospitals. The system has been suggested to be enlarged nationally to 
encompass all U.S. blood centres (Wallace EL, 2003). Pereira tested a stochastic 
model to simulate performance of a hospital blood bank inventory that held only 
unassigned inventories (type and screen procedure, where specific RBCs are not 
cross-matched to particular patients) (Pereira A, 2005). RBC shortage and outdate 
rates increased with the variation in daily demand for transfusion, the major 
parameter in defining the performance of blood inventory. The findings suggested 
adjusting the residual shelf life of RBCs to the variation in daily usage. 
Managing inventories efficiently has proven complex. Maximum use of blood 
resources requires recognizing the interrelations of supply and demand, and 
happens through the combined efforts of the parties involved. Redesigning 
computer and networking systems to operate with actual data on blood supplies 
and usage to be visible for all parties in the supply chain would contribute to 
minimizing shortages and outdates and allow timely transfusions (Chapman J, 
2007). 
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5.3 cosTs in blood esTablishmenTs
Cost efficiency analyses of blood supply and transfusion are not available in the 
literature, whereas cost accounting and cost comparisons have received more 
attention. 
Costs of a blood centre can be demonstrated as four basic functions (Figure 3). 
All of these functions involve specialized equipment and materials, such as special 
blood bag systems, automated blood scales, and sterile docking devices. A Finnish 
study reported that materials and screening tests of a blood service accounted for 
24% of all blood transfusion costs (Rautonen J, 2007). Purchases represented 16% 
of the RBC unit cost in Canadian blood centres (Tretiak R et al., 1996). Categorized 
by functions, blood collection and WB processing have been suggested to involve 
more than two thirds of direct blood service costs (Guest JF et al., 1998; Custer B 
et al., 2005). 
 
Blood collection, production, and distribution were evaluated to account for 40% 
of the cost of RBC transfusion in six Canadian blood centres (Tretiak R et al., 1996). 
A later study found that these functions represented more than half of the total RBC 
transfusion cost (Amin M et al., 2004). A British study concluded that even 76% of 
annual direct costs of blood transfusion were carried by blood centres (Guest JF et 
al., 1998). A recent analysis of the costs of blood supply in Finland suggested that 
blood service costs account for a similar proportion (76%) of blood transfusion costs 
(excluding the costs of the transfusion event) (Rautonen J, 2007).
The donor time designated to donation is considered a productivity cost, and it 
has been reported to be directly or indirectly equivalent to 6%-16% of the blood 
product cost (Guest JF et al., 1998; Amin M et al., 2004; Custer B et al., 2005). In 
a U.S. study, a community blood supply model was developed to evaluate donor 
requirements on blood supply and cost of blood. The unit cost of obtaining blood 
was lowest (196 USD including donor’s time in addition to production cost) among 
older males (55 years or older) and highest (216 USD) among young females (16–24 
years) (Custer B et al., 2005). A Canadian study revealed substantial variation in 
RBC transfusion costs across hospitals. The mean opportunity cost of donor time was 
evaluated at 18.21 USD (7% of transfusion costs) (Amin M et al., 2004). 
DONOR RECRUITmENT AND BLOOD COLLECTION
BLOOD TESTING
BLOOD COmpONENT pREpARATION
INVENTORy AND DELIVERy
Figure 3 Cost elements in blood establishments
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Few efforts have been made to evaluate the cost of individual product in the 
conditions of joint production. Jacobs et al. developed a flowchart that separated 
processes from their related inputs and outputs and allowed common costs to be 
allocated to each product (1992). Guest et al. stratified costs according to blood 
product and estimated that RBCs accounted for 60% and PLTs for 23% of production 
and issuing costs in blood services in the U.K. in 1994/1995. In a later comparative 
study from 2000/2001, RBCs and PLTs accounted for 77% and 7%, respectively, of 
blood service costs (Guest JF et al., 1998; Varney SJ and Guest JF, 2003). The annual 
cost of provision and transfusion of blood products was reported to increase by 256% 
in the U.K. between 1994 and 2001.
From an economic and management perspective, labour represents the most 
costly input in blood banking. In a Canadian study, 41% of the mean cost of blood 
collection, preparation, and distribution were attributed directly to labour cost (Amin 
M et al., 2004). Tretiak et al. categorized blood transfusion costs into four stages: 
collection, production, distribution, and delivery. Personnel was the primary cost 
driver representing 60% of the RBC unit cost (1996). According to Pereira, personnel 
accounts for more than 70% of all transfusion costs (Pereira A, 2002).
Introduction of new measures to improve the safety of blood transfusions has 
markedly increased costs in blood centres (AuBuchon JP et al., 2001; Goodnough LT 
et al., 2003). At the same time, the availability of blood has decreased, compelling 
blood centres to enhance efforts and financing to recruit donors (Custer B et al., 
2005). Although increasing costs have accumulated in assaying for infection markers 
and maintaining a sufficient donor base, improving the productivity of labour should 
be seen as a target in strategies to contain the costs of blood transfusion (Pereira A, 
2002).
Cost efficiency analysis is an inseparable part of an assessment of economic 
performance. Blood services would benefit from comparisons that evaluate the 
real cost efficiency of the whole blood supply chain from donation to transfusion. If 
measuring cost efficiency is possible, it enables estimation of savings potential. 
5.4 efficiency research in healTh care 
The economic importance of health care started to grow rapidly in the 1950s. For 
example, in Finland the percentage of GDP allocated to health care grew from 3.9% 
(1960) to 9.3% (1992), fell after that as a result of cuts in health care resources 
and accelerated growth of GDP to 6.6% in 2000, and has grown steadily since to 
7.5% in 2004. The growth has been significant also in other European countries 
(OECD, www.oecd.org). Increasing public expenditure on health care has motivated 
the search for sources of rising costs and measures of assessing the performance of 
health care organisations and technologies.   
Efficiency analyses were more widely adapted by the health care sector in the 
1980s. Absorbing a significant proportion of public spending, hospitals have been the 
focus of such analyses. Performance of not-for-profit organisations, e.g., hospitals, 
has often been measured by evaluating their productivity and efficiency (Grosskopf 
S and Valdmanis V, 1987; Magnussen J, 1996; Smet M, 2007), and there has been 
growing interest in comparing their relative performance (Ferrier G and Valdmanis V, 
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1996; Linna M and Häkkinen U, 1999). The non-parametric DEA was applied in a cost 
efficiency analysis, which revealed marked differences among and within Finnish and 
Norwegian hospitals (Linna M et al., 2006).
It is generally assumed that a large production volume allows more efficient 
use of resources (scale efficiency). In a study measuring the efficiency of 64 long-
term care units in Finland, larger units seemed to operate more efficiently than 
smaller units (Bjorkgren MA et al., 2001). Another Finnish study revealed no clear 
association between technical efficiency and the size of 114 long-term care units 
(Laine J et al., 2005). A Salter diagram was applied to illustrate the efficiency 
distribution in the units.
5.4.1 Efficiency concepts    
In the health care literature, the same concepts are often used to indicate quite 
different measures of performance. To clearly express what the concepts actually mean 
in various contexts, it is useful to distinguish among the four elements of health care 
activity (Sintonen H and Pekurinen M, 2006). 
The first element is the inputs, the resources (manpower, capital) available for 
health care. Their amount can be measured commensurably by costs, by their 
monetary value. The second element is the production process, where resources 
are combined to produce the third element, the output. The output is composed 
of different services, products, or technologies, which in turn produce changes in 
health status. These changes in health status, or health effects, are referred to as 
effectiveness, which represents the fourth element. 
inPutS 
resources 
costs
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     unit costs
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Figure 4 Elements of health care activity and the relationships between them 
(adapted from Sintonen H and Pekurinen M, 2006)
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There are two approaches to assessing the performance of health care. One 
concentrates on exploring the performance in terms of the relationship between the 
inputs and output as measured by the different services, products, or technologies 
produced. This approach can be called the productivity school. It aims to find the 
best ways of converting inputs, measured either in physical or monetary terms, into 
output. In this school, often-used measures of performance are productivity, technical 
efficiency, productive efficiency, operative efficiency, allocative efficiency, and cost 
efficiency. This school does not pay explicit attention to the health effects of output. 
There may be several reasons for that, such as an assumption that all services, 
products, or technologies that health care produces are beneficial to health and thus 
effective (which clearly does not hold in practice) or that measuring the differential 
health effects at least commensurably is too difficult to be worth the effort.   
The other approach concentrates on exploring the performance of health care in 
terms of the relationship between the inputs and effectiveness. The most often used 
measures of performance are referred to as cost effectiveness or efficiency. This 
school aims to identify the best ways to convert inputs, measured in monetary terms, 
into effectiveness. Health effects are measured explicitly because of the idea that 
the health effects produced are the ultimate measures of output and that different 
services, products, or technologies are just necessary intermediate outputs; thus, in 
a sense, they are the inputs to the production of ultimate outputs, i.e., health effects. 
In addition, different services, products, or technologies can result in zero or even 
negative effectiveness, and the positive effectiveness can vary a great deal; therefore, 
the assumption that all services, products, or technologies are beneficial to health is 
unwarranted. Thus, the concept of efficiency should be reserved to indicate this more 
fundamental relationship between costs (inputs) and effectiveness, and this approach 
constitutes the “real” efficiency school (Sintonen H and Pekurinen M, 2006). 
In summary, when encountering the various versions of the concept of efficiency, it 
is necessary to be clear about how the output is measured. If the output is measured 
in terms of services, products, or technologies produced, we are dealing with a 
productivity analysis. If it is measured in terms of effectiveness (health effects), then 
the approach is the “real” efficiency analysis.
The present study belongs to the realm of productivity analysis. Below, the meaning 
of different efficiency concepts used in this area is briefly clarified. 
5.4.2 Measures of efficiency in productivity analysis
Simple measures of productivity can be defined as the ratio of the output produced to 
the inputs used in a certain period of time. In the calculation of total productivity, all 
inputs are included. In case of capital productivity, the output is divided by the capital. 
A measure of labour productivity can be obtained by dividing the output by the amount 
of labour used. In the case of multiple outputs and inputs, they have to be weighted 
in an appropriate way to achieve unidimensionality on both sides. Usually the outputs 
and inputs are weighted by their monetary values. These simple measures do not tell, 
however, how well different production units perform in producing a given output and 
whether they are performing in the best possible way given the technology. 
Technical efficiency was defined by Koopmans as follows: a production unit is 
technically efficient if an increase in any output requires a reduction in at least one 
other output or an increase in at least one input, and if a reduction in any input 
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requires an increase in at least one other input or a reduction in at least one output 
(Koopmans T, 1951). Technical efﬁciency occurs when the maximum amount of 
output is produced with a given set of inputs (output-oriented technical efﬁciency), 
or when the minimum amount of inputs is required to produce a given output (input-
oriented technical efﬁciency) in a certain time. Unit A is thus technically efﬁcient 
compared to unit B if unit A uses less of at least one input and not more of the other 
inputs to achieve the same output than unit B.
The idea of technical efﬁciency can be illustrated with Figure 5. The shaded area 
L(y) represents a certain amount of output that can be produced with different 
combinations of inputs x1 and x2. Isoquant Isoq L(y) combines the production units, 
which produce that output with the least combinations of inputs. The isoquant locating 
closest to the origin is also called the efﬁciency frontier. Now according to the deﬁnition 
of Koopmans, combinations xC, xD, xB, and λAxA are technically efﬁcient, whereas 
xA is not. It is questionable though, whether combination λAxA can be regarded as 
technically efﬁcient because combination xB can produce the same output with less 
input x1 without using any more input x2. Thus, there is slack in the use of x1, and 
in the deﬁnition of Farrell (1957), therefore, λAxA is not technically efﬁcient. Some 
authors use productive or operational efﬁciency as synonyms of technical efﬁciency 
(Rosko MD, 1990; Parkin D and Hollingsworth B, 1997). 
Figure 5  Illustration of 
the concepts of technical 
and allocative efﬁciency 
(source Linna M, 1999)
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Usually inputs are not free but have to be acquired at a price. The budget lines 
w, w’, and w’’ represent different amounts of money (budgets) by which a different 
combination of x1 and x2 can be acquired. The budget line w indicates all combinations 
of x1 and x2 that can be obtained with this budget. Lines w’ and w’’ represent higher 
budgets. They are parallel to w, and the slope of the lines is determined by the 
relative prices of inputs x1 and x2.
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Assuming that the production units aim at cost minimisation, then the input 
combination xD is the least costly, as the lowest budget line touches the isoquant 
at xD. Thus, that combination is called allocatively efficient because with it the 
unit production costs (production costs/output) are at their minimum. This least 
unit cost combination can also be called cost efficient. Allocative efficiency thus 
coincides with cost efficiency, and maximisation of cost efficiency thus implies 
minimisation of unit cost. The ratio of minimum unit cost to observed unit cost 
provides a measure of cost efficiency. In Figure 5, the measure of cost efficiency 
for combination xB is w/w’. A measure of cost inefficiency or savings potential for 
combination xB in comparison to the cost efficient combination is 1 – (w/w’).
It is generally assumed that large production volumes result in scale efficiency 
or economies of scale, also called increasing returns to scale (IRS), meaning that 
with increasing volumes, unit production costs would decrease. Such a situation 
would prevail if an equal percentage increase in all inputs were to result in a greater 
percentage increase in output. Constant returns to scale (CRS) would prevail if 
an equal percentage increase in all inputs were to result in the same percentage 
increase in output. Decreasing returns to scale (DRS) would prevail if an equal 
percentage increase in all inputs were to result in a lower percentage increase in 
output.
5.4.3 Empirical efficiency studies in blood banking
Efficiency analyses are scarce in blood banking. In an early study, the labour 
efficiency index (sum of standard output units divided by staff working time, 
median 0.32, range 0.12-0.98) calculated in 40 hospital-based blood banks 
suggested a considerable amount of slack time for the staff of most of blood 
banks (Lam HC et al., 1994). A case study identified quality tools, such as 
the fishbone diagram, that could contribute to improving the labour efficiency 
(Butch SH, 1998). Pitocco and Sexton evaluated the operational efficiency in 70 
U.S. blood banks and found that 34 operated inefficiently (2005). The collective 
output of PLTs could be increased by 17% and that of RBCs by 7.3% if the 
inefficiency decreased by half. Pereira found 6 of 71 blood banks to be technically 
efficient under the assumption of CRS and defined the optimal size of a blood 
bank to be 75,000-100,000 produced RBCs per year (2006). In his recent study, 
Pereira concluded that regulated competition between blood suppliers would 
help alleviate diseconomies of blood transfusion (2007).    
Conclusions about the scale efficiency in blood services are controversial. Pierskalla 
found that blood banks producing 50,000 to 70,000 RBCs annually operate most 
efficiently (Pierskalla WP et al., 1987). Pereira concluded that most of the technical 
inefficiency was scale independent in 39 (55%) of 71 surveyed blood centres 
operating under the assumption of IRS (2006). Pitocco and Sexton demonstrated 
the efficiency frontier to be characterized by IRS and suggested that blood centres 
can increase their operational efficiency and gain economies of scale, for example, 
through a merger (2005). 
Until now, comparative efficiency studies have mainly been national (Bell AM et 
al., 2008). 
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5.4.4 Methods of analysing efficiency 
Data envelopment analysis
Data envelopment analysis (DEA) is a linear non-parametric technique first introduced 
by Farrell and later developed by Charnes, Cooper, and Rhodes (Farrell MJ, 1957; 
Charnes A et al., 1978). DEA is based on relative efficiency measures, and in this 
framework a unit is judged to be efficient if it is operating on the best practice 
production frontier (efficiency frontier). The efficiency frontier is a numerical definition 
of the most efficient combination of inputs to produce a given output. Efficiency of 
any production unit can be measured by comparison with this frontier. 
Specific features of DEA make it applicable for efficiency analysis. DEA requires 
a minimal assumption for the functional specification of the underlying production 
technology. DEA also enables accommodation of several inputs and outputs with 
different units of measurement, such as physical parameters or monetary units. A 
priori chosen weights are not required for the aggregation of variables. DEA has also 
proven feasible in small sample sets. Importantly, in addition to identifying inefficient 
production units, DEA outlines direction for eliminating inefficiency (Rosko MD, 1990). 
There are restrictions that may limit the usefulness of DEA. Unit-specific efficiency 
scores may be sensitive to influential observations, which can have an effect on the 
placement of the efficiency frontier. Particularly in small sample sizes, DEA models 
are sensitive to the selection and the number of variables. Too-complex models can 
result in misspecification of efficiency (Rosko MD, 1990; Smith P, 1997). Because 
DEA is a non-parametric method, it converges slowly with statistical inference and 
hypothesis testing.
DEA has been widely used in studies evaluating the productive or technical efficiency 
of hospitals (Hollingsworth B and Parkin D, 1995; Magnussen J, 1996; Hollingsworth 
B and Parkin D, 2003). A Finnish study applied DEA for assessing the cost efficiency of 
Finnish and Norwegian hospitals. Cost differences were equalized by adjusting a part 
of the hospital operating costs with purchasing power parities (PPP) (Linna M et al., 
2006). Purchasing power parities are rates of currency conversion developed to account 
for cross-national variation in prices and to make them comparable (Purchasing power 
parity, http://ec.europa.eu/eurostat). In comparison, the exchange rate between two 
currencies takes into account only the ratio of the prices.   
DEA has been employed recently by two U.S. studies addressing efficiency in blood 
centres. In one study, DEA was applied with an output orientation assuming variable 
returns to scale (VRS) (Pitocco C and Sexton TR, 2005). The other study explored the 
technical efficiency in 71 blood centres assuming DEA with an input orientation under 
CRS and VRS, finding that 28% of the centres were operating in the CRS region, 55% 
in the IRS region, and 37% in the DRS region (Pereira A, 2006).  
Parametric methods and DEA  
Stochastic frontier analysis (SFA) is a parametric frontier method that, like DEA, is 
based on relative efficiency measures and on estimates of a best practice frontier 
(Meeusen W and van den Broeck J, 1977). SFA defines best practices by calculating a 
theoretical best-practice frontier, while that of DEA is based on actual firms (production 
units). While DEA lacks a stochastic component by assuming that all departures 
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from the efficiency frontier are due to inefficiency, SFA allows for the separation 
of random errors and statistical noise from inefficiency (Rosko MD and Mutter RL, 
2008). Inefficiency estimates obtained by SFA may thus be lower compared to those 
of DEA. The use of SFA in hospital applications has been criticized, because unlike 
DEA, it requires strong assumptions about the functional form (e.g., the production 
technology or the distribution of inefficiency). Using an incorrect functional form 
may confound inefficiency estimates in SFA (Newhouse JP, 1994). Compared to 
DEA, SFA is less sensitive to data variations (e.g., outliers) because SFA estimates 
are based on average parameter values in the regression equation (Jacobs R, 2001). 
The availability of data may also influence the choice of an appropriate method. 
SFA is more focused on cost inefficiency than on technical inefficiency, which is the 
primary focus of DEA analyses. If input price data are available, a cost-oriented SFA 
might be an appropriate method to evaluate the cost (in)efficiency (Kumbhakar S 
and Lovell C, 2000).
A stochastic frontier regression (SFR) and DEA have been applied for scoring 
hospital efficiency (Chirikos TN and Sear AM, 2000), and cost indicators were used 
in modelling. SFR and DEA suggested convergent results of efficiency at the industry 
level but yielded divergent evidence about characteristics of the best and worst 
performers. In a comparison of results obtained using DEA and parametric methods 
in the measurement of hospital technical efficiency, the highest correlations were 
found in the efficiency scores between CRS-DEA and parametric models. Correlation 
was higher in models with one output than in two-output models (Siciliani L, 2006). 
Frontier efficiency analyses have gained widespread application in improving 
managerial performance and providing data for support of health policy decisions in 
hospitals and other health care organisations (Berger A and Humphrey D, 1997).
5.4.5 international comparison
Interest in comparing the relative performance of health systems has been growing, 
although international comparisons are still scarce in the literature (Mobley Lee 
Rivers MJ, 2006; Steinmann L et al., 2004). In performance evaluation, efficiency has 
been considered one of most challenging objectives of a health system, and many 
OECD countries are developing indicators for measuring, for example, productivity 
(Hurst J and Jee-Hughes M, 2001). Common performance measures would serve as 
indicators for efficiency benchmarking internationally. 
International cost comparisons must be based on a common currency. Applying 
only exchange rates tends to overvalue real consumption in countries with a relatively 
low price level and overvalue consumption in countries with a higher price level. This 
outcome leads to comparisons that may confuse price differences with differences in 
real health expenditure. For assessing the cost efficiency of health organisations, PPP 
adjustment can be used for input and output prices in cross-national cost comparisons 
(Linna M et al., 2006). 
International research on the comparability of the efficiency in blood banking has 
not been conducted so far. 
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6 AImS OF THE STUDy
 
The main aim of this study was to explore and compare retrospectively the relative 
technical efficiency, especially from a management (labour resources) and economic 
(total costs) perspective, of a number of European blood component preparation 
departments in three consecutive years. 
The specific aims were:
Article I. To describe the preparation methods and production volumes of PLTs and 
the PLT discard rates in a number of European blood centres and to analyse whether 
preparation methods and production volumes would help to explain the possible 
differences in PLT discard rates. 
Article II. To assess the technical efficiency of component preparation departments 
and to analyse factors that affect the efficiency. In this analysis, differences in the 
use of resources (inputs) received special emphasis. The hypothesis was that large 
departments could be more efficient. 
Article III. To explore to what extent the discard rates of RBCs and PLTs are associated 
with the technical efficiency of component preparation.
Article IV. To assess the labour efficiency and the cost efficiency of component 
production departments and on the basis of the results estimate possible savings 
potential in the departments. 
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7 mATERIALS AND mETHODS
7.1 daTa sources
Ethical review was not included because only statistical data were involved. The 
names of the participating centres were coded to protect their anonymity. 
 7.1.1 participating centres
Originally, 22 blood centres were invited to participate in this study. Seventeen centres 
from 10 countries in continental Europe, Great Britain, and Scandinavia accepted the 
invitation (Appendix I, Participating centres). The centres were of different sizes in 
terms of the annual WB collection volumes and were integrated into university hospitals 
(seven blood banks), were national institutions (five national institutes), or were part of 
the Red Cross organisation (five blood services). All seven hospital-based blood banks 
and one Red Cross centre represented the Nordic countries and four Red Cross centres 
and all national institutes were from Central and Southern Europe. All centres were 
considered non-profit organisations with voluntary, non-remunerated blood donation. 
Both Red Cross centres and national institutes were categorized as centralized blood 
service systems, a specific element of which was the subject of this study.
This study focused on the component preparation departments of the centres 
(blood establishments, blood banks). The departments functioned as production 
units; they prepared and issued blood products according to demand in their service 
area with the exception of one centre, which supplied only part of the PLTs required in 
its area. Because processes of component production are similar among the centres, 
the preparation departments were chosen as models. Blood centres, in contrast, 
cannot be similarly “forced”.
   
7.1.2 data collection
The data were gathered from component preparation departments by standardized, 
structured questionnaires via the Internet for the years 2000-2002 during the period 
of July 2003–March 2004 (Appendix II, Data questionnaire; Appendix III, Guidance 
for replying). The questionnaires were managed technically by Digium Oy, Turku. 
To complete and clarify the data, several site visits were performed in 2002-2004. 
Participants were given an opportunity to comment on the questions through a draft 
questionnaire distributed beforehand. 
The questionnaires contained 92 questions divided into seven sections: explanatory 
data, output data, economic data, labour input in component processing, technical 
data of processing PLTs, long-term capital and capital cost input, and short-term 
capital cost input, i.e., consumables. Response guidance was included with selected 
questions. A specific question concerning the proportion of discarded PLTs of all 
produced PLTs in 2003 and 2004 received a reply from 11 blood centres from eight 
countries. Because the data were obtained retrospectively, questions to monitor the 
reliability of answers and to promote uniform data interpretation were included, and 
the coherence of the answers was tested. All the data were displayed in a matrix of 
observations, which was evaluated regarding its completeness, and approved. 
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7.1.3 material of original articles
The number of participants in original articles varied from 13 to 17 (Table 1). The 
blood centres that provided the most complete data set formed the basis for the 
present study. Because all data were not available from all centres, the pooled sample 
size varied. The number of samples in each analysis is indicated in the results.
Table 1  Material of original articles
Article Number of  participants
Pooled  
sample sizea
Reasons for exclusion from the pooled 
sample of 51 – missing data or year
I Variation of platelet pro-
duction and discard rates 
in 17 blood centres repre-
senting 10 European coun-
tries from 2000 to 2002
17
in some analyses
51
44 Aphaeresis-PLTs of Db7 (n=3 individual 
years); discarded PLTs of D6 (n=3); year 
2001 data of D14 (n=1)
II International comparison 
of the technical efficiency 
of component preparation 
16 46 Aphaeresis-PLTs of D7 (n=3); year 2001 
data of D11 and D14 (n=2)
III Discarded cellular com-
ponents and the technical 
efficiency of component 
preparation
13 37 Aphaeresis-PLTs of D7 (n=3); discarded 
PLTs of D6 (n=3); discarded RBCs of D1 
and D2 (n=6); year 2001 data of D11 and 
D14 (n=2)
IV Working hours and pro-
duced cellular components 
as variables to evaluate 
blood bank efficiency
13
cost analysis
37
35
Aphaeresis-PLTs of D7 (n=3); discarded PLTs 
of D6 (n=3); discarded RBCs of D1 and D2 
(n=6); year 2001 data of D11 and D14 (n=2)
Above mentioned missing data (n=14) 
and mean hourly earnings of year 2001 of 
D12 and D13 (n=2)
a The number of individual years for which data were available
b D refers to the blood component preparation department of the centre
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Variables of the original articles are listed in Table 2. The processed blood components 
were assumed to meet the requirements of the Blood Directive and the Council of 
Europe’s “Guide to the preparation, use and quality assurance of blood components”. 
Regardless of production method, a PLT unit was defined as PLTs derived from one 
WB collection with a PLT count of greater than 60 × 109, which was also taken as a 
single unit equivalent (Guide, 2007). 
Article I. Working hours included the hours of full-time, temporary, and part-time 
personnel. Produced RBCs comprised the total of leukocyte-reduced and non-filtered 
RBCs as single units. Produced PLTs comprised all PLTs produced by any method. 
Discarded PLTs comprised the total PLT loss, including those wasted in production 
and those that became outdated, regardless of production method. PLT production 
methods included the BC, PRP, and aphaeresis methods. The discard rate was 
calculated by dividing the number of discards by the number of produced PLTs/RBCs. 
The labour index was calculated by dividing the total of produced PLTs + RBCs by the 
number of working hours.
Article II. Premises included the space (m2) that was used for preparation of blood 
components, aphaeresis, and the immediate office facilities. Equipment comprised 
the centrifuges, separators, and aphaeresis devices that were purchased or hired, 
including those in stock. Lead time of PLTs was the time from WB collection to a ready 
PLT product. 
Table 2  Variables in original articles
Article Variables Described Site characteristics Analysed
I WB collections
Working hours
Produced RBCs and PLTs
Discarded RBCs and PLTs
PLT production 
methods
Discard rates of 
RBCs and PLTs
Not tested Descriptive analysis
Labour index
Input variables Output variables
II WB collections
Working hours
Premises
Equipment
Produced RBCs  
and PLTs  
(FFP)
WB resting time
Proportion of leukodepleted RBCs  
from all RBCs
Proportion of BCs from WB
Proportion of BC-PLTs from all PLTs
Lead time of PLTs
Proportion of discarded PLTs  
from all PLTs
Technical efficiency
Scale efficiency
III WB collections
Aphaeresis-PLTs
Discarded RBCs 
and PLTs
Produced  
RBCs and PLTs
WB collections  
lost
Not tested Technical efficiency
Scale efficiency
IV Working hours
Estimated total 
costs
Produced  
RBCs and PLTs
Discarded  
RBCs and PLTs
Savings potential
Waste cost
Unit cost
Not tested Labour efficiency
Cost efficiency
Scale efficiency
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Article III. PLTs derived from aphaeresis comprised PLT units as single unit equivalent. 
The proportion of WB collections lost was defined as (total RBC loss + total PLT loss)/
collected WB units. 
Article IV. Estimated total costs were calculated based on the assumption that the 
costs of working hours represent 20% of the total department costs. Savings potential 
(observed inefficiency) was the distance of achieved efficiency from the efficiency 
frontier (savings potential = 1.0 – efficiency score). Waste cost was the unit cost 
multiplied by the number of discarded RBCs and PLTs. Unit cost was the estimated 
total costs divided by the number of produced RBCs and PLTs. 
7.2 meThods
Article I: Descriptive statistics were used to categorize the blood centres according 
to size and production-related characteristics, such as the PLT preparation methods, 
discard rate, and labour index. 
Articles II-IV: DEA (Farrell MJ, 1957) was used to determine an efficiency frontier 
and to calculate efficiency scores for the preparation departments. The non-
parametric Mann-Whitney U test was used to compare groups, and simple linear 
regression was used to analyse the association between the descriptive data of 
groups and DEA efficiency models. A two-sided p value of <0.05 was deemed 
statistically significant. A Salter diagram was applied to illustrate the distribution of 
technical efficiency scores (II). 
Article III: The independent samples Mann-Whitney U test was used to analyse 
the impact of discards on the efficiency scores; the Pearson correlation coefficient 
was used to explore the linear association between variables (inputs and outputs 
in DEA models); the Tobit regression model was used to explain the variance in the 
efficiency scores (Tobin J, 1958; Greene WH, 1998; Wooldridge JM, 2002); the year 
dummies was used to demonstrate a time trend in the efficiency scores; and the 
Kolmogorov statistic and Shapiro-Wilk statistic were used for testing the normality 
of the residuals distribution.
Article IV: Purchasing power parities were applied to adjust the costs for the working 
hours and to make them comparable between countries (Purchasing power parity, 
http://ec.europa.eu/eurostat). PPP of private consumption including households and 
non-profit institutions was selected for the present study. Calculation of the costs was 
based on the mean hourly health and social work earnings (class N) of each country 
for the years 2000, 2001, and 2002 (United Nations Statistic Division, International 
Standard Industrial Classification (ISIC), Economic and Social Statistical Classifications, 
http://unstats.un.org/unsd/class; Earnings per hour/month, http://laborsta.ilo.org).
Mean hourly earnings were adjusted with the PPP to obtain the mean cost for 
a working hour of each department (country). This value was then multiplied by 
the number of annual working hours. The following exceptions were made: (1) 
Mean hourly earnings from 2004 of class N were implemented because class N 
was not available for 2000–2002 (D9). (2) The local currencies from 2000 (D5, 
D16) and from 2000-2001 (D8) were first converted to euro using fixed conversion 
coefficients for the years. (3) Mean monthly earnings were divided by 160 to obtain 
the costs for the mean hourly earnings (D3, D12, D13, D14). 
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Figure 6 DEA efficiency 
definition with simplified 
production technology of 
one output and two inputs. 
The shaded area indicates 
all feasible combinations of 
inputs 1 and 2 to produce 
output y.
 All units on the efficiency 
frontier (southwest edge of 
shaded area) operate ef-
ficiently by producing the 
same output with minimal 
combinations of the two in-
puts. Units C and D are effi-
cient and receive a technical 
efficiency score of 1.0. Unit 
A does not lie on the frontier 
and is technically inefficient 
(score is less than 1.0). The 
technical efficiency score for 
unit A was calculated by the ratio λ=OF/OA, which is directly related to unit A’s distance from 
the efficiency frontier. Unit A’s input vector xA can be contracted radially up to point F and still 
remain capable of producing output y (Linna M, 1999).
7.2.1 data envelopment analysis 
DEA was employed to evaluate the efficiency of the component preparation departments 
(Farrell MJ, 1957; Charnes A et al., 1978). Linear programming techniques were 
used to estimate the efficiency frontier and to calculate the unit-specific efficiency 
scores for each department. The departments lying on the frontier received a score 
of 1.0 (100% efficiency). Less-efficient departments received a score lower than 
1.0 but higher than 0. For example, if a department’s efficiency score was 0.80, its 
inefficiency was 20%, and it could use 20% less of input resources to produce the 
same output. In the present study, the departments that received a score lower than 
0.90 were rated as technically inefficient (II, III). In measures of labour efficiency 
and cost efficiency (IV), scores lower than 1.0 indicated inefficiency. An example of 
the DEA technical efficiency definition is given in Figure 6.
DEA enables calculation of the efficiency scores under various assumptions of scale 
economies. Comparing the individual efficiency scores by CRS and VRS, it is possible 
to determine whether a production unit is situated in the region of IRS, DRS, or CRS 
and make inferences about the benefits of down- or upsizing its production. In the 
present study, the efficiency scores were calculated from two alternative assumptions, 
CRS (CRS-DEA) and VRS (VRS-DEA, II) (Table 3). 
The purpose of the analysis affects the choice of orientation in DEA. An input 
orientation aims at recognizing the potential reductions in the input while keeping 
the output constant. An output orientation aims at recognizing the potential increases 
in the output while keeping the input constant. Blood centres are usually required to 
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meet the hospital demand in their service area, that is, to scale the product volumes 
(output) according to the estimated demand. They can more freely adjust the use of 
resources (input) needed for the production. Thus, the analysis was focused on the 
efficiency with the minimum amount of inputs required to produce a given output 
(input orientation). 
Estimation of the cost differences of RBC/PLT preparation was one of the goals of 
this study. Because market prices (output prices) for blood products are not available, 
DEA cost efficiency was used as an approximation. 
7.2.2 dea models
Variables for the DEA models were selected based on the aim to illustrate the 
efficiency (technical, labour, cost) in relation to component production. Several 
different models were created and tested. In article II, four DEA models were tested. 
Two of the models, DEA 3 and DEA 4, were selected for further analysis. Models DEA 
1 and DEA 2 did not reveal differences between the departments. In the DEA model 
in article III, discarded RBCs and PLTs were technically treated as inputs, although 
they are conceptually considered a negative output of production. Article IV included 
an empirical cost model, DEA/Ct, in which the estimated total costs of component 
preparation were chosen as the input variable. DEA/Wh (working hours) was applied 
for the relative labour efficiency. Selected DEA models are shown in Table 3. 
Table 3  Models of DEA used in the comparative analyses
Article Model Input Output Pooled sample sizea Assumption
I DEA 1 Working hours, premises, WB collections RBCs, PLTs 46 CRSb
DEA 2 Working hours, WB collections RBCs, PLTs 46 CRS
DEA 3 Working hours, equipment RBCs, PLTs 46 CRS, VRSc
DEA 4 Working hours, equipment, WB 
collections
RBCs, PLTs 46 CRS, VRS
III DEA WB collections, aphaeresis-PLTs, 
discarded RBCs and PLTs
RBCs, PLTs 37 CRS
IV DEA/Wh Working hours RBCs, PLTs 37 CRS
DEA/Ctd Estimated total costs RBCs, PLTs 35 CRS
a The number of individual years for which data were available
b CRS, constant returns to scale
c VRS, variable returns to scale
d Ct, cost total
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8 RESULTS 
8.1 plaTeleT producTion (i)
8.1.1 production volumes and methods (i)
The number of annual WB collections varied from 8,880 to 290,352 in the centres. The 
total annual number of WB collected by the centres decreased slightly over the study 
period. The hospital-based centres were significantly smaller than the other centres 
(median 38,000 and 99,407, respectively, p<0.0001, Mann-Whitney U test).
The number of produced RBCs and the total number of PLTs produced by any 
method varied greatly among the centres (Figure 7A, B). In 2002, 73% of all PLTs 
were produced by the BC method, 23% by aphaeresis, and 4% by the PRP method. 
The total number of PLTs produced increased by 5.6% and that of RBCs remained the 
same from 2000 to 2002. 
The mean proportion of WB donations used for preparation of BC-PLTs was 35% in 
2000 (min 8, max 55%), rising to 41% in 2002 (min 8, max 64%; Figure 8). BC-PLTs 
were prepared in 15 of 17 blood centres. 
All centres also collected PLTs by aphaeresis, and two centres collected all PLTs by 
this method. The proportion of PLTs produced by the BC method from all PLTs varied 
from 36% to 99%, and that of aphaeresis-derived PLTs from 1.1% to 100% between 
the centres. The amount of PRP-PLTs prepared in one centre decreased over time.
8.1.2 discard rates of plTs and rbcs (i, iii)
The proportion of discarded PLTs from all PLTs produced varied widely (the annual PLT 
discard rate was from 3.9% to 31%; Figure 7B). The mean annual PLT discard rate 
(13%) remained in the same range (15% in 2000 and 12% in 2002) in all centres, 
including the four centres reporting prolonged shelf lives (6-7 days instead of 5 days) 
throughout the study period. In all, discard rates demonstrated similar levels and 
variation between centres in 2003 to 2004 (2-year mean 14%, range 3.8%-24%, 
n=11), as in 2000 to 2002. Because the discards were given by the centres as the 
total loss of PLTs regardless of production method, the causes leading to discards 
could not be further evaluated. 
The annual PLT discard rates were, to some extent, associated with production 
volumes (r=0.35, p=0.03, n=37, DEA). This association could not be demonstrated 
statistically in study I using the three-year mean values in the analysis. The mean 
RBC discard rate was 4.5%, varying annually from 0.2% to 7.7% (Figure 7A). 
Annual RBC discard rates demonstrated a similar association with production 
volumes (r=0.38, p=0.02, n=37, DEA). No other reasons were identified for the 
discard rates of each centre.        
No significant correlation was found between the RBC and PLT discard rates (r=-
0.16, p=0.35, n=37), although a close linear relationship of RBCs to the production 
volume of PLTs was observed (r=0.95, II).
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Figure 7 Production volumes (bars) and discard rates (diamonds) of RBCs (A) and of 
PLTs (B) in the participating centres. Some data were missing (D1, D2, RBC discards; 
D6, PLT discards; D7, aphaeresis-PLTs; D11, D14, year 2001).
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Figure 8 Proportion of WB collections used for preparation of BC-PLTs in the centres during 
the three study years. Dark bars indicate the number of WB collections, light bars the number 
of BCs. Diamonds indicate the proportion BC-PLTs produced from WB collections. Data for the 
year 2001 were missing (D14). Two centres (D3 and D13) prepared all PLTs by aphaeresis.
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8.2 Technical efficiency (ii)
Moderate differences were shown in technical efficiency (median score 0.92, range 
0.72-1.0, n=46) among departments, when WB collections, working hours, and 
equipment were used as inputs and the produced RBCs and PLTs as outputs (DEA 
4). Removing the non-substitutable input, WB, from the model revealed marked 
variation in efficiency (DEA 3, median 0.60, range 0.41-1.0, n=46). Twelve of sixteen 
departments were labelled inefficient because their annual efficiency scores were less 
than 0.90 in all study years. This outcome suggests that there was an excess use 
of labour resources (working hours) and/or production equipment in the inefficient 
departments. Compared with the efficient departments, they used more hours per 
WB collection to produce the RBCs and PLTs. Only four departments, all from different 
countries, were technically efficient in both DEA 3 and DEA 4.
Technical efficiency decreased in the observation period in three departments in 
DEA 3. In the two small departments, the efficiency decreased from 1.0 to 0.54 and 
from 0.88 to 0.68, respectively. In both cases, this decrease could be explained by 
an increase both in the working hours (124% and 20%, respectively) and in the 
amount of equipment (140% and 29%, respectively) as the departments started 
developing their PLT production methods and enhanced PLT volumes by 20% and 
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11%, respectively. In the third department, which implemented new programs in 
the component preparation, the number of produced RBCs and PLTs declined by 
4.6% and 7.8%, respectively, and the number of working hours increased by 22%. 
Although these three departments performed inefficiently in DEA 3, they were rated 
efficient based on DEA 4. Technical efficiency remained essentially at the same level 
in 13 departments through the study years.  
Assuming VRS, the technical efficiency remained at the same level in 11 departments 
compared to the results of CRS.
Technical efficiency could not be explained by site characteristics derived from 
production-related technology, such as resting time of WB, proportion of leukocyte-
reduced RBCs from all RBCs, proportion of BCs from WB, proportion of BC-PLTs from 
all PLTs produced, lead time of PLTs, or proportion of discarded PLTs from all PLTs.
 
 8.2.1 Discard rate and technical efficiency (III)
Technical efficiency scores varied from 0.82 to 1.0, when the WB collections, 
aphaeresis-PLTs, and discarded RBCs and PLTs (negative output) were in the analysis 
as inputs (DEA). The produced RBCs and PLTs were outputs. More than half (51%) 
of departments achieved the highest efficiency (score 1.0). Efficiency was lowest 
in two departments (score 0.82 both) throughout the study period. In the most 
inefficient department, the mean annual PLT discard rate was 22%. It was a large 
centre, annually collecting more than 250,000 WB units and deriving 39% of all PLTs 
from aphaeresis. In the other department, the annual PLT discard rate varied from 
12% to 29%. It collected about 30,000 WB units per year and derived all PLTs from 
aphaeresis.
There was a tendency for technical efficiency to be higher when the (theoretical) 
proportion of lost WB donations (total RBC+PLT loss) from all collections was low 
(Mann-Whitney U test). 
Waste cost (IV)   
The median waste cost incurred by the discarded RBCs and PLTs was higher in the 
four largest departments (median 9.4%, range 5.6%-11.3%, n=12) than in all the 
other (smaller) departments (median 6.6%, range 3.4%-12.4%, n=23, p=0.004, 
Mann-Whitney U test). 
8.3 labour efficiency and cosT efficiency (i, iV)
Labour efficiency (DEA/Wh) varied significantly, from 0.25 to 1.0 (median score 0.47), 
when working hours were used as the input. With the estimated total costs as the 
input (DEA/Ct), the variation of efficiency was even greater, from 0.13 to 1.0 (median 
0.25). Cost efficiency demonstrated lower scores compared to labour efficiency in 
most departments. A “sensitivity analysis” performed with a higher proportion of 
labour from the estimated total costs did not demonstrate changes in the order of 
departments, which is in line with the basic assumption of DEA.
The labour index (mean 4.2 units per hour, min 2.4, max 7.3, n=15, data from D7 
and 14 were missing) was not associated with the total number of produced RBCs 
and PLTs, the proportion of leukocyte-reduced RBCs, the PLT preparation method, 
or the proportion of discarded PLTs. 
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As expected, the correlation was strong (r=0.94, p<0.0001, n=37) between labour 
efficiency and labour index. A marked correlation also existed between cost efficiency 
and labour index (r=0.55, p=0.0007, n=35). 
The two most labour-efficient departments were both hospital-based blood banks, 
in which the annual efficiency scores varied from 0.79 to 1.0 and the produced RBCs 
and PLTs from 25,104 to 106,340 units. One of these two departments was also one 
of the most cost-efficient departments, in which scores varied between 0.66 and 
0.71, even if these are fairly low in absolute terms. Another department received an 
efficiency score of 1.0 in the first year, but its efficiency decreased to 0.45 during the 
three study years. This decrease could be due to technological changes made in the 
production of blood components. 
Efficiency of component preparation departments was analysed using several DEA 
models, which included various inputs or input combinations. Changing input variables 
also changed the outcome, as expected (Figure 9). Additionally, over time, changes in 
efficiency could be observed in departments during the three-year study period.  
figure 9 Efficiency scores for departments obtained using DEA models in 2002 (bars). Not all data 
were available from all centres. The bars indicate models (with different inputs): white=DEA 3 (working 
hours, equipment), light grey=DEA 4 (working hours, equipment, WB collections), darker grey=DEA 
(WB collections, aphaeresis-PLTs, discarded RBCs and PLTs), gradient = DEA/Wh (working hours), and 
black=DEA/Ct (estimated total costs). White circles indicate the number of produced RBCs and PLTs in 
2002. Departments are ranked from left to right by the amount of production (smallest-largest).
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8.3.1 savings potential (iV)
In six of the thirteen departments, the savings potential, both in labour and costs, 
was more than 50% in all study years. When evaluated using the estimated total 
costs (DEA/Ct), 10 departments had a savings potential of more than 50%. The 
savings potential was similar in both analyses. Theoretically, this implies an annual 
savings potential of more than two million euros in several inefficient departments. 
No association was observed between savings potential and the number of WB 
collections. 
 
8.3.2 unit cost (iV)
A unit cost was obtained by dividing the estimated total costs by the number of produced 
RBCs and PLTs. The unit cost varied widely (median 17.00 €, range 3.40 €-32.60 €, 
n=35) and did not depend on production volume. 
8.4 scale efficiency (ii-iV)
There was little indication of scale economies in the technical efficiency of larger 
preparation departments (processing more than 60,000 WB units per year). They 
had consistently an efficiency score over 0.85 (median 0.96, range 0.87–1.0, n=20, 
DEA 4). On the other hand, there were efficient and inefficient departments among 
those processing fewer than 60,000 WB units (median 0.91, range 0.72–1.00, n=26). 
The difference between the efficiency scores of the two groups was not significant 
(p=0.19).
The scale advantage disappeared when labour efficiency and cost efficiency were 
assessed. No link between scale efficiency and low discard rate was observed.
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9 DISCUSSION AND CONCLUSIONS
Along with the abating resources and increasing expenses of the blood system, 
enhancing efficiency has become a necessary challenge in blood banking (Pereira 
A, 2007). The focus of studies has been in national evaluations, only a few of which 
have contained efficiency analyses (Pitocco C and Sexton TR, 2005; Pereira A, 
2006; Bell AM et al., 2008). These analyses revealed that the relative technical and 
operational efficiency could be markedly improved in the inefficient centres. The 
present study was designed to evaluate the relative efficiency of blood component 
preparation in European blood centres. Interest in benchmarking blood bank 
activities internationally has increased recently. As an example, a joint conference 
was arranged between the European Blood Alliance (EBA) and America’s Blood 
Centers (ABC) (MacPherson J, 2007). The outcome of the conference suggested a 
need for improving the co-operation and the efficiency of the logistic chain between 
blood centres and hospitals. Efficiency comparisons, even cross-national, have 
been published in other health care fields (Steinmann L et al., 2004; Linna M et al., 
2006), but international analyses that benchmark performance in blood banking 
have not been reported previously.
The approach of the present study was multidisciplinary, involving elements 
from medical, technical, and economic perspectives. The technical, labour, and 
cost efficiency analysis addressed the blood component production subject to the 
highest medical safety requirements (Blood Directive; Guide). DEA was considered 
an appropriate method because it could be applied for a small sample size and 
allowed description of inputs and outputs in different physical units. The inputs and 
outputs were selected to illustrate the production factors within the limits of data. 
Complete data from three consecutive years were available from most of the centres. 
Analytical models were created that may be used to compare several aspects of blood 
component production, even internationally.
Outdating and timely provisions of blood components 
Efforts to create a safer blood supply continue to result in the development of new 
technologies (Allain JP et al., 2005). Blood components can be distributed only after 
release from infectious testing. As a consequence, components are held a longer time 
in storage, which may contribute to outdating of PLTs. Outdated PLTs may represent as 
much as a fifth part of all produced PLTs (Sullivan MT and Wallace EL, 2005). Because 
the outdated components should be considered a lost resource, the extension of the 
shelf life of cellular components and efficient management of the blood supply chain 
are the targets of extensive research. 
The aim of establishing an efficient blood supply and component preparation is to 
ensure the timely availability of blood products. Although the number of products 
prepared for security stock was included in the production volumes, their relative 
proportion from all prepared products may have varied according to the obligations 
set for maintenance of the stock. The present study does not, however, take a stance 
on whether the production departments, efficient or not, were able to respond in a 
timely way to the demand for blood products.  
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Efficiency analysis
Technical efficiency varied widely among the component preparation departments. 
The efficiency was not associated significantly with site characteristics, such as WB 
resting time, proportion of filtered RBCs from all RBCs, proportion of BCs from WB, 
proportion of BC-PLTs from all PLTs produced, or proportion of PLT discards from all PLTs. 
Heterogeneity of blood centres (size, production volume, administrative structure) may 
have distorted the efficiency frontier (Pitocco C and Sexton TR, 2005). 
There was a tendency for the largest departments to be technically more efficient, 
when the working hours, the equipment, and the WB collections were used as inputs 
(DEA 4, II). When the inputs were replaced by the WB collections, aphaeresis-
PLTs, and aggregated discarded RBCs and PLTs, the scale advantage disappeared 
(DEA, III). Neither were the higher labour efficiency scores associated with larger 
production volumes (DEA/Wh). A similar result was obtained in a recent comparative 
labour productivity analysis, which evaluated the efficiency of total collections 
(WB+aphaeresis) per employee in eight blood centres (Bell AM et al., 2008). Although 
conclusions about scale efficiency are controversial in blood banking (Pierskalla WP 
et al., 1987; Pitocco C and Sexton TR, 2005; Pereira A, 2006), increasing the sample 
size or redesigning the input/output combinations may demonstrate clear economies 
of scale.   
The labour efficiency was evaluated by the number of working hours. It was 
assumed that the working hours were addressed correctly to the component 
preparation departments. The hours may, however, contain some uncertainty owing 
to differences in the allocation of resources for overlapping positions. Because the 
data on total production volumes were available, it was possible to calculate the 
number of units (RBCs+PLTs) produced per hour (labour index). When the labour 
efficiency was assessed by DEA (DEA/Wh), the RBCs and PLTs were treated as two 
outputs. The results were similar to those obtained using the simple labour index. The 
efficiency varied greatly among the departments. In comparison with the technical 
efficiency, the variation was wider and the level was lower in the labour efficiency. 
This variation may be due to different variables in DEA. In DEA, the departments are 
rated according to their relative performance. Because the outliers affect the rating in 
small samples, there may have been such an effect in the DEA scoring. 
The cost efficiency of component preparation was assessed using an empirical cost 
model in which the estimated total costs of component preparation were used as an 
input. The total costs were approximated by the aid of the data on working hours 
(Pereira A, 2007). International comparisons that contain cost data must be based 
on a common currency. PPP incorporates the currency conversion rates to account 
for price differences, considering a basket of goods and calculating the price (output 
price) of this basket in each country using local currency. In the present study, the 
PPP-adjusted mean costs of working hours (input price) were used to compare the 
cost differences among countries. 
The analysis revealed a substantial variation in cost efficiency. The efficiency 
levels were in general lower than those in technical efficiency. The technically 
efficient departments were thus not necessarily cost efficient. The observed 
inefficiency identified remarkable savings potential in 10 departments. This kind 
of benchmarking may provide an approximation for blood establishments of lost 
resources in relation to the other participants. It was also possible to calculate 
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the cost for the proportion of discarded PLTs and RBCs (waste cost) and further 
evaluate the unit costs. The costs per blood unit varied widely with a median cost 
of 17.00 €. A Canadian study evaluated the mean cost of processing a blood unit at 
16.65 USD (6% of transfusion costs) (Amin M et al., 2004). In the present study, 
the experimental analysis was interesting because blood products are included in 
hospitals’ prices for disease-related groups. 
Real cost efficiency was not the aim of the present study. Measuring cost 
efficiency requires specification of an economic objective and data on market prices. 
Statistical data on costs, including salaries, are scarce, even nationally. The hours 
were purely physical items that did not include, for example, costs of overtime or 
working on Sundays. Labour is considered a cost-driver, and many activities are 
labour intensive, requiring qualified employees to ensure the supply of blood under 
stochastic demand. Lack of relevant comparable cost data has prevented blood 
establishments from being able to identify sources of inefficiency.
Methodological aspects
In health care, questionnaires have been generally used to collect information for 
epidemiological purposes and for various registries. Questionnaires are quick and 
cost effective, but disadvantages include the risk that respondents misinterpret 
questions or answer superficially, particularly where multiple languages are common. 
A similar risk is caused by the lack of uniform terminology. Current computer 
systems would allow replacement of questionnaires by real-time, Web-based data 
collection. The contents of data fields should be prospectively defined to ensure 
commensurability. The data would thus be transferred directly via an interface to a 
research coordinator, enabling on-line analysis of coordinated data. 
DEA measures relative efficiency within the sample. If the department with the 
highest efficiency score (1.0) were tested in another sample (or by other variables), 
it might perform less efficiently. A small sample size would be a problem if other 
methods were used. DEA is, however, less sensitive to a small sample size. The size 
variation of the departments was unexpectedly wide, which could have weakened 
the relative performance of smaller departments in the sample. Physical variables 
were applicable in DEA analysis of technical efficiency, whereas more uncertainty 
was associated with the cost analysis. Because monetary data were not available 
publicly from all centres, the total costs were estimated using PPP-adjusted costs for 
the working hours. The PPP-adjustment was assumed to improve the comparability, 
although the cost estimates would still contain some inaccuracy (Linna M et al., 
2006).  
Study limitations
Product-mix could be one site characteristic affecting efficiency. To simplify the 
models, the sums of RBCs and PLTs, respectively, were used as variables, although 
some centres may have had considerable amounts of different products. 
When the FFP was included as one of the outputs in the analysis of technical efficiency 
(DEA 3, DEA 4) the main results did not change. One large department received a 
lower efficiency score in DEA 4, and another small hospital blood bank achieved 
higher technical efficiency. FFP was not included in the cost efficiency analysis as an 
output, although it may have affected the result (Zingsem J et al., 2002).
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Conclusions          
Both ethical and economic reasons advocate for more profound research in the future. 
The present study evaluated data from European blood centres (years 2000-2002; 
specific additional question for 2003-2004). The results demonstrated remarkable 
inefficiencies and lost outputs. The results, however, are retrospective and should be 
re-evaluated in a prospective setting.
Because obtaining the data was complex, synchronized, real-time data should be 
made available. These data are needed, for example, for terminology so that the 
studies can allow online analysis and active management improvement. The present 
study provided applicable DEA models for the blood bank community. Because 
discarded cellular blood components can be considered a lost production output, they 
require excess labour resources. Although some amount of discards is unavoidable, 
what an acceptable amount is remains to be identified.   
Although the collection of WB was dictated by the demand for RBCs, it was interesting 
to note a close association of the number of produced RBCs to the production volume 
of PLTs. This association suggested a similar demand ratio for RBCs and PLTs in the 
service areas of the blood centres. 
Labour and supplies are the main cost-drivers in blood centres, and labour is subject 
to efficiency improvements because labour inefficiency is found to be a major cause 
of technical inefficiency. By reallocating excess labour resources, blood centres may 
reduce the inefficiency observed in the benchmarking. Considerable waste cost was 
observed in this novel approach to studying efficiency, and the lost production output 
(discarded blood components) thus should not be ignored. 
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AppENDIX I
The following centres participated in the study. I sincerely thank my colleagues for 
their contribution in providing me with the original data:
Blood Transfusion Centre, Aarhus University Hospital, Skejby, Denmark (N Grunnet, 
MD, PhD; B Samuelsen, MD)
Austrian Red Cross Blood Transfusion Services, Vienna, Austria (E Menichetti, MD, 
PhD; M Winter, MD)
Blood Bank, Haukeland University Hospital, Bergen, Norway (T Hervig, MD, PhD)
Blood Bank, Huddinge University Hospital, Stockholm, Sweden (A Shanwell, MD, 
PhD)
Blood Bank of Oslo, Ullevaal University Hospital, Oslo, Norway (HE Heier, MD, PhD, 
MHA; S Hvitsand, MSc)
Blood Bank of the City of Copenhagen, Copenhagen, Denmark (P Johansson, MD, 
MPA)
Blood Bank, University Hospital, Tromsoe, Norway (A Husebekk, MD, PhD; BH 
Johnsen, MD)
Blood Transfusion Centre Antwerpen, Antwerpen, Belgium (M Baeten, MD) 
Blood Transfusion Service, Swiss Red Cross, Aarau, Switzerland (R Schwabe, PhD; J 
Burger, MD)
Blood Transfusion Service, Swiss Red Cross, Vaud, Switzerland (R Schwabe, PhD; 
D-H Vu, MD)
Finnish Red Cross Blood Service, Helsinki, Finland (A Hemminki, PhD)
Funen Transfusion Service, Odense, Denmark (J Georgsen, MD; K Titlestad, MD, 
PhD)
National Blood Service, NHS, Birmingham, the United Kingdom (V Sydenham, 
ACMA)
Northern Ireland Blood Transfusion Service, NHS, Belfast, the United Kingdom (WM 
McClelland, MB FRCPath)
Portuguese Blood Institute, Lisbon, Portugal (VMC Marques, Hospital Administrator)
Sanquin Blood Supply Foundation, Amsterdam, the Netherlands (E Jansen, GHM)
Welsh Blood Service, NHS, Pontyclun, the United Kingdom (J Lewis, Acting Finance 
Manager) 
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Status of Blood Service  1. 
1 = Red Cross  2 = National (foundation etc)  3 = Hospital based
Name and location of Blood Centre2. 
Number of whole blood donations3. 
Number of donations by Apheresis4. 
Number of HLA- and HPA-typed platelet units produced by 5. 
Apheresis upon request
Volume of whole blood collected at a donation (ml)6. 
What determined total number of whole blood units to be 7. 
collected annually?
Use of platelets per 1 000 inhabitants in the country  8. 
(unit = platelets of one donation)
Were platelets collected from both new and known donors?    9. 
1 = Known 2 = Both
Is there a policy to give platelets of patients’ own blood group 10. 
only? 1 = Yes 2 = No 3 = Varies
What proportion of the provided platelets were ABO and RhD 11. 
-identical? Give a rough estimation in percentage.
2000 2001 2002
5/Efficiency Study 
22 July 2003  
Data Questionnaire 
Costs and efficiency of processing platelet concentrates. Comparative study 
of three common methods: buffy coat, platelet-rich plasma and apheresis
Abbreviations: BC = buffy coat, PRP = platelet-rich plasma FFP = fresh-frozen plasma 
OUTPUT DATA 2000 2001 2002
Methods of platelet preparation, please mark (1 = In use) 12. 
BC ................................................................................. 
Aprehesis ........................................................................ 
PRP ................................................................................
Total number of platelet units (as single units incl. special 13. 
products) processed by BC method
Total number of platelet units (as single units incl. special 14. 
products) processed by Apheresis
Total number of platelet units (as single units incl. special 15. 
products) processed by PRP method
Total number of all discarded platelet units (as single units)16. 
Number of platelet units discarded due to outdating (as 17. 
single units)
Number of produced leucocyte- 18. 
depleted adult platelet concentrates (as single units incl. spe-
cial products) by production method  
BC ................................................................................. 
Aprehesis ........................................................................ 
PRP ................................................................................
Number of produced leucocyte-depleted paediatric platelet 19. 
concentrates (as single units incl. special products) by pro-
duction method 
BC ................................................................................. 
Aprehesis ........................................................................ 
PRP ................................................................................
EXPLANATORY DATA
AppENDIX II
| 57 |
Number of produced (non-filtered) adult red cell concentrates20. 
Number of produced leucocyte-depleted (filtered) adult red 21. 
cell concentrates
Number of produced paediatric (non-filtered) red cell con-22. 
centrates
Number of produced paediatric leucocyte-depleted (filtered) 23. 
red cell concentrates
Total number of all discarded red cell concentrates24. 
Number of red cell concentrates discarded due to outdating25. 
Average unit volume and number of produced adult FFP units 26. 
by production method 
Whole blood (unit volume, ml)  .......................................... 
Apheresis (unit volume, ml)  ............................................. 
Whole blood .................................................................... 
Aprehesis ........................................................................
Average unit volume and number of produced paediatric FFP 27. 
units by production method 
Whole blood (unit volume, ml)  .......................................... 
Apheresis (unit volume, ml)  ............................................. 
Whole blood .................................................................... 
Aprehesis ........................................................................
Definition of the main platelet product28. 
Number of produced main platelet products 29. 
Pools of 1 units ................................................................ 
Pools of 2 units ................................................................ 
Pools of 3 units ................................................................ 
Pools of 4 units ................................................................ 
Pools of 5 units ................................................................ 
Pools of 6 units ................................................................
Number of discarded main platelet products  30. 
(incl. outdated platelets) 
Pools of 1 units ................................................................ 
Pools of 2 units ................................................................ 
Pools of 3 units ................................................................ 
Pools of 4 units ................................................................ 
Pools of 5 units ................................................................ 
Pools of 6 units ................................................................
2000 2001 2002OUTPUT DATA
2000 2001 2002ECONOMIC DATA
Number of adult platelet concentrates delivered to hospitals 31. 
(as single units incl. special products)
Number of paediatric platelet concentrates delivered to hospi-32. 
tals (as single units incl. special products)
Sales (invoiced, EUR) of adult platelet concentrates (incl. 33. 
special products)
Sales (invoiced, EUR) of paediatric platelet concentrates (incl. 34. 
special products)
Number of leucocyte-depleted (filtered) adult red cell units 35. 
delivered to hospitals
Number of leucocyte-depleted (filtered) paediatric red cell 36. 
units delivered to hospitals
Number of non-filtered adult red cell units delivered to 37. 
hospitals
Number of non-filtered paediatric red cell units delivered to 38. 
hospitals
Sales (invoiced, EUR) of leucocyte-depleted (filtered) adult 39. 
red cells
Sales (invoiced, EUR) of leucocyte-depleted (filtered) 40. 
paediatric red cells
Sales (invoiced, EUR) of non-filtered adult red cells41. 
Sales (invoiced, EUR) of non-filtered paediatric red cells42. 
Number of adult FFP units delivered to hospitals, by 43. 
production method 
Whole blood .................................................................... 
Aprehesis...................................... ..................................
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Number of paediatric FFP units delivered to hospitals, by 44. 
production method 
Whole blood .................................................................... 
Aprehesis ........................................................................
Sales (invoiced, EUR) of adult FFP units, by production method 45. 
Whole blood .................................................................... 
Aprehesis ........................................................................
Sales (invoiced, EUR) of paediatric FFP units, by production 46. 
method 
Whole blood .................................................................... 
Aprehesis ........................................................................
Total sales of all blood products produced in the centre (EUR) 47. 
(excl. plasma for fractionation and plasma derived products)
2000 2001 2002ECONOMIC DATA
2000 2001 2002LABOUR INPUT IN COMPONENT PROCESSING
Please categorise the employees into two groups according to 48. 
their position: 
I Leading position  ........................................................... 
(supervisors, dep. heads, chiefs) 
II Operational position ...................................................... 
(all other staff, nurses, lab. workers, technicians etc)
Please estimate the number of employees in permanent 49. 
positions, per year
Please estimate the number of employees in temporary or 50. 
part-time positions, per year
Number of theoretical working hours of the employees in 51. 
permanent positions, per year
Number of theoretical working hours of the employees in 52. 
temporary, part-time or other short-term positions, per year
Total number of absence hours, per year53. 
Total of taxable salaries (EUR), per year54. 
Additional salary expenses (EUR), per year55. 
2000 2001 2002TEChNICAL DATA OF PROCESSING PLATELETS
Mean recovery of platelets per unit  56. 
(Council of Europe Guide PC > 60 x 109/single unit 
equivalent)
Recovery of platelets per leucocyte-depleted platelet unit57. 
Mean residual leucocyte count per leucocyte-depleted platelet 58. 
unit (Council of Europe Guide < 0.2 x 106/unit)
Average lead-time of processing platelets (h)59. 
Was whole blood stored (“resting”) before first 60. 
centrifugation?  
If yes, for how long (h)?
Number of bags in centrifuge at a time61. 
Were pools stored (“resting”) before adding storage solution?  62. 
If yes, for how long (h)?
Pooling of 1, 2, 3, 4, 5 or 6 units. Please mark the number.63. 
Pooling of platelets (1 = In use) 64. 
of same ABO blood group .................................................. 
selected blood groups..................... .................................. 
any blood groups .............................................................
Average volume of platelet concentrate (pool or single, 65. 
please specify) (ml) 
Pools of 1 units 
Pools of 2 units 
Pools of 3 units 
Pools of 4 units 
Pools of 5 units 
Pools of 6 units
Size of ordinary adult therapeutic dose of platelets in hospital66. 
Was integrated storage bag/platelet filter system used for 67. 
platelets?  1 = Yes 2 = No
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Was plasma used as preserve solution for platelets? (1 = In use) 68. 
BC ................................................................................. 
Aprehesis ........................................................................ 
PRP ................................................................................
Was pathogen inactivation used and if yes, since when? Mark 69. 
the year  1 = Yes 2 = No
Was bacterial culture used and if yes, for the process control only 70. 
or as criterion to release the products for use? 1 = Yes 2 = No  
Process control ................................................................ 
As criterion to release .......................................................
Shelf-life of platelet concentrates and time when 71. 
calculation starts
2000 2001 2002TEChNICAL DATA OF PROCESSING PLATELETS
Area of premises in m72. 2 used for component processing 
Average market value of own premises per m2 (EUR) 73. 
Current price (rent) per m74. 2
Number of all centrifuges in blood component processing75. 
Please estimate the number of centrifuges in regular use76. 
Please give an estimation of the average age (in years) of the 77. 
centrifuges in regular use
Number of all separation devices in blood component 78. 
processing
Please estimate the number of separation devices in regular use79. 
Please give an estimation of the average age (in years) of the 80. 
separation devices in regular use
Number of all Apheresis devices in blood component 81. 
processing
Please estimate the number of Apheresis devices in regular use82. 
Please give an estimation of the average age (in years) of the 83. 
Apheresis devices in regular use
2000 2001 2002Long-tErm CapitaL anD CapitaL Cost input
2000 2001 2002short-tErm CapitaL Cost input ConsumabLEs
Total purchase cost (EUR) of the bags and bag systems used 84. 
for whole blood collection in the centre, per year 
a) with leucocyte removal filter for red cells......................... 
b) without leucocyte removal filter for red cells .................... 
c) with leucocyte removal filter for whole blood ....................
Please guesstimate, which proportion (in percentage) of the 85. 
bags expressed in question 84 was used for processing of 
platelets, per year
Total purchase cost (EUR) of the stand-alone leucocyte 86. 
removal filters for red cells, per year
Total purchase cost (EUR) of the stand-alone leucocyte removal 87. 
filters for platelet concentrates, per year
Total purchase cost (EUR) of the stand-alone storage bags for 88. 
platelets, per year
Total purchase cost (EUR) of the integrated storage bag/89. 
leucocyte removal filters for platelet concentrates, per year
Total purchase cost (EUR) of storage (preserve) solutions for 90. 
platelets, per year
Total purchase cost (EUR) of sterile connections for 91. 
processing platelets, per year
a) What proportion (in percentage) of platelets were cultured  92. 
to detect bacterial contamination? 
b) Please estimate the total cost (EUR) of culturing, per year 
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(2x) Name and location of Blood Centre
The purpose is to explore the efficiency and costs of the component preparation in one blood centre 
chosen by you. Thus, the whole blood service is no object for this survey. The FRC BTS has four blood 
centres preparing blood components in Finland. The biggest one is located in Helsinki and was chosen 
to participate in this study. If the name or/and location of the centre has changed, please advise the 
latest information.       
(3x) Number of whole blood donations
Please give the total number of all donations that took place in the centre or at other sites, which collected 
and delivered the whole blood units to be further processed in the centre. Helsinki is a big processing cen-
tre. Thus the number of Helsinki centre includes the donations at Helsinki site, but also in other territories 
at smaller centres, which sent the donated blood for processing in the Helsinki centre.
(10x) is there a policy to give platelets of patients’ own blood group only?
The practice varies in Finnish hospitals. The FRC BTS initiated discussion to unify the practice and 
prefer producing the platelets from blood groups A and O and the FFP from blood groups B and AB. 
This would decrease the outdating and allow to optimise the stock levels.
(13x) total number of platelet units (as single units incl. special products) processed by 
BC method
The definition “single unit” means the platelets received from one donation. The number should in-
clude both the adult and paediatric platelet units including the further derived special products. 
(14x) total number of platelet units (as single units incl. special products) processed by 
Apheresis
The definition “single unit” means the platelets received from one donation. The number should in-
clude both the adult and paediatric platelet units including the further derived special products.
(15x) total number of platelet units (as single units incl. special products) processed by 
PRP method
The definition “single unit” means the platelets received from one donation. The number should in-
clude both the adult and paediatric platelet units including the further derived special products.
(16x) Total number of all discarded platelet units (as single units)
The definition “single unit” means the platelets received from one donation. The number should in-
clude both the adult and paediatric platelet units regardless of the reason of discard.
(17x) Number of platelet units discarded due to outdating (as single units)
The definition “single unit” means the platelets received from one donation. The number should in-
clude both the adult and paediatric platelet units discarded due to outdating.
(33x) sales (invoiced, Eur) of adult platelet concentrates (incl. special products)
The sales include the total sum of yearly invoices or transfer prices to the hospitals. If there were no 
money transactions between the blood centre and hospital, leave the column empty. Leave off the 
decimals and bring up or round off to the nearest full figure. Please use the same method of answer-
ing the further questions 34, 39-42 and 45-47 for sales.
(47x) total sales of all blood products in the centre (excl. plasma for fractionation and 
plasma derived products)
Please include both the adult and paediatric red cell and platelet products, FFPs, whole blood concen-
trates and possible sales of outdated red cell units. The sales of raw plasma, plasma for fractionation 
and plasma derived products not to be included.
(48x) please categorise the employees into two groups according to their position
Please include the employees who worked directly in the component processing department in per-
manent, temporary or part-time and in leading or operational positions and were on the payroll of the 
department during 2000, 2001 and 2002. If it is difficult to give exact figures, please give your best 
estimation of the average monthly number of employees. 
(49x) please estimate the number of employees in permanent positions, per year
Just pick up the number of the employees having been in permanent positions. If it is difficult to give 
exact figures, please figure out your best estimation. 
(50x) please estimate the number of employees in temporary or part-time positions, per year
Just pick up the number of the employees having been in temporary, part-time or other short-term 
positions. If it is difficult to give exact figures, please give your best estimation.
(51x) number of theoretical working hours of the employees in permanent positions, per year
Please multiply the number of statutory (or agreed) weekly working hours by 52 (weeks per year) 
5/Efficiency Study 
22 July 2003  
Data Questionnaire 
guidance for replying
Costs and efficiency of processing platelet concentrates. Comparative study 
of three common methods: buffy coat, platelet-rich plasma and apheresis
Abbreviations: BC = buffy coat, PRP = platelet-rich plasma FFP = fresh-frozen plasma
AppENDIX III
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and by the number of permanent employees. Example from the FRC BTS: 38,15 h x 52 x 47 = 93 
239 h. Additionally: 30,00 h x 52 x 5 = 7 800 h and total 101 039 h. Leave off the decimals and 
bring up or round off to the nearest full figure. If it is difficult to give exact figures, please give your 
best estimation.
(52x) number of theoretical working hours of the employees in temporary, part-time or 
other short-term positions, per year 
Please calculate or give your best estimation on the agreed working hours of temporary, part-time or 
other short-term employees per each year.
(53x) total number of absence hours, per year
In order to calculate the effective working hours, all the absence hours should be included. The ab-
sence hours consist of the statutory vacations and other absences by any reason. Please include the 
yearly absence hours of both permanent and temporary, part-time or other short-term employees. 
Please calculate or give your best estimation.  
(54x) total of taxable salaries (Eur), per year
Please include the taxable salaries of all employees having been on the payroll of the blood process-
ing department. Do not include the additional salary expenses paid by the employer.
(55x) additional salary expenses (Eur), per year
The purpose is to calculate the total of additional salary expenses that the blood centre was obliged 
to pay in connection with monthly salaries. In the FRC BTS the additional salary expenses are called 
as social payments representing about 24-26% of the taxable salary. The social payment consists of 
the social security fee, employee pension fee and the accident insurance.  
(59x) average lead-time of processing the platelets
The time starts from the moment of collecting the blood and ends when the platelet bag is in the 
“swingboard” in the guarantee or delivery store of the blood centre or hospital. Give your best esti-
mation for the average lead-time.   
(72x) Area of premises in m2 used for component processing
Include the premises normally used for processing, but also those being in reserve but not used regu-
larly. Include the storage and office premises, which are used by the employees of the component 
preparation. Do not include the premises for plasma fractionation.   
(73x) average market value of own premises per m2 (Eur)
In case the processing premises are of your own property, please estimate their current market value 
per m2. The current market value indicates the value of the premises, if they were sold out on the 
free market. 
(75x) Number of all centrifuges in blood component processing
Include the total number of centrifuges located in the component preparation department regardless 
of their purpose of use. 
(76x) Please estimate the number of centrifuges in regular use
Include all centrifuges regularly used in the component preparation regardless of their purpose of use. 
(77x) please give an estimation for the average age (in years) of the centrifuges in 
regular use
Example: 10 centrifuges purchased in 1992 and 4 in 1996. 10 x 9 (years 1992-2000) and 4 x 5 
(1996-2000) makes 110 years. 110 divided by 14 (nr of centrifuges) gives the average age of 7,9 
years.  You can also give your best estimation. 
(78x) number of all separation devices in blood component processing
Include the total number of separation devices located in the component preparation department 
regardless of their purpose of use.
(79x) please estimate the number of separation devices in regular use
Include all separation devices regularly used in the component preparation department regardless of 
their purpose of use.
(80x) please give an estimation for the average age (in years) of the separation devices in 
regular use
Please calculate according to the example of the question 77 or give your best estimation.
(81x) number of all apheresis devices in blood component processing
Include the total number of Apheresis devices used in the component preparation department regard-
less of their purpose of use.
(82x) please estimate the number of apheresis devices in regular use 
Include all Apheresis devices regularly used in the component preparation department regardless of 
their purpose of use.
(83x) please give an estimation for the average age (in years) of the apheresis devices in 
regular use
Please calculate according to the example of the question 77 or give your best estimation.
(84x) total purchase cost (Eur) of the bags and bag systems used for whole blood collec-
tion in the centre, per year
Purchase contracts are often done for more than one year. The deliveries take place and are invoiced 
several times during the year. The purchase costs consist of the sum of the invoices paid during the 
year in question. Please mark the sum on the column of each year and mark with “0” (zero) to indi-
cate the year with no purchases. Use the same method of answering all further questions 86-91 for 
purchase costs.
(92bx) please estimate the total cost (Eur) of culturing, per year
Include the costs, if the culturing was performed as a criterion to release the platelet products for use 
or as a routine/occasional follow-up and control procedure. 
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